Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
3-20-2020 3:00 PM

Characterization and Enhancement of Local Drug Delivery in
Orthopaedic Infection
Tina Khazaee, The University of Western Ontario
Supervisor: David W. Holdsworth, Robarts Research Institute
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Medical Biophysics
© Tina Khazaee 2020

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Medical Biophysics Commons

Recommended Citation
Khazaee, Tina, "Characterization and Enhancement of Local Drug Delivery in Orthopaedic Infection"
(2020). Electronic Thesis and Dissertation Repository. 6851.
https://ir.lib.uwo.ca/etd/6851

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
The delivery of antibiotics is an important component of therapy for orthopedic devicerelated infections (ODRI). In this study, we have investigated new techniques to characterize
and enhance antibiotic delivery for ODRI. Characterization of small-molecule diffusion is
essential to the development of drug-delivery systems. We have developed a quantitative,
non-invasive, longitudinal, micro-CT technique to quantify the diffusion of small-molecules
in an intact phantom. We employed a radio-opaque molecule (i.e., Iohexol) as a surrogate for
commonly used antibiotics (e.g., Vancomycin). We characterized diffusion from a finite-core
carrier into an agar, tissue-equivalent phantom. The estimate of the diffusion coefficient was
derived from the analysis of radial diffusion distance of Iohexol and the cumulative release
amount of this drug surrogate. This micro-CT method enabled us to describe the elution of
small-molecules from enhanced carriers within a porous metal scaffold. To enhance
antibiotic delivery, we designed and fabricated gyroid-based scaffolds with appropriate
mechanical properties and filled with Iohexol-loaded carriers. Diffusion characteristics
within the porous structures were evaluated using the micro-CT technique.

Keywords
Diffusion, small-molecules, local drug delivery, micro-CT, drug-surrogate, contrast agent,
orthopedic device-related infection, 3D-printed porous scaffold.
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Summary for Lay Audience
Orthopedic device-related infection is a devastating problem that is associated with metal
implants. Infection can occur any time after primary orthopedic surgery, and can result in
severe residual disability and in-hospital mortality; thus, it is a burden for the health care
system and for patients. In this work, we focused on infection near orthopedic joint implants,
since more than 130,000 knee and hip joint replacement surgeries are performed each year in
Canada and thousands become infected.
The current treatment for implant-associated infection is two-stage revision surgery. The first
challenge is to eliminate the infection; thus, patients would undergo invasive surgery to
remove the infected components. During this stage, the patient would also receive systemic
antibiotics in addition to local antibiotics to the target joint.
Local treatment would be performed by placing a temporary component that can be loaded
with antibiotics. This temporary component maintains the structure of the joint and releases
drugs to the target tissue. However, current antibiotic carriers are not highly effective for
local infection treatment and release an insufficient amount of the drugs to the target tissue.
After 6-8 weeks, if the infection is eradicated, temporary carriers should be removed due to
the low mechanical properties of these carriers; hence, a second surgery would be performed
to remove the carrier and place the final revision implants.
In this work, our goal was to understand how antibiotics are being released through carriers
to the surrounding tissue. We used a micro-CT imaging technique to monitor the release of a
drug mimic from a commonly used orthopedic carrier to a tissue-equivalent phantom and
characterized the release. We were able to optimize the imaging technique for evaluating the
diffusion of the drug from various carriers, qualitatively, and quantitatively.
Upon understanding of drug release, we proposed the application of highly-porous 3Dprinted metal structures in combination with current antibiotic carriers. The pores of the
structure can be filled with the antibiotic-loaded carrier to satisfy the needs for local infection
treatment, while the material properties (i.e., titanium alloy) would maintain the mechanical
strength that is required for a joint implant; thus can be retained in the joint and eliminate the
need for multiple surgeries.
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Chapter 1
1

Introduction to Orthopedic Device-Related Infection

This thesis addresses unmet needs related to orthopedic device-related infections (ODRI),
which includes infections near fracture-fixation components that are used during trauma
surgery [1-4], as well as peri-prosthetic joint infections (PJI) near orthopedic components
(such as hip and knee replacements) [5-8]. Infections – along with component wear and
loosening – are a major cause of surgical revision of total joint replacements (TJR) [9]. While
significant improvements in orthopedic surgical devices have reduced the risk of mechanical
failure in trauma and joint replacements, relatively little progress has been made in the area
of infection and mainly PJI [9]. PJI is one of the most common reasons for early revision
(within five years of primary surgery) of both hip and knee replacements[10]. In North
America, orthopedic surgical site infections affect over 100,000 people each year [11, 12]. In
the US, recent data show that the percentage of knee arthroplasty revision surgeries due to
infection has grown from 13% in 2012 to 22% in 2018 [13]. Infection can lead to
catastrophic complications, including severe, residual disability, limb amputation, and death;
PJI doubles the risk of in-hospital mortality [14].
Infection is a growing problem in orthopedic surgery. It is now the number one reason for
early revision of hip and knee replacements in Canada [10]. The number of total knee and hip
joint replacements continues to rise in Canada, with a 17% increase in the number of
arthroplasties performed over the past five years [10]. Unfortunately, 9700 (or 7%) of these
surgeries are implant revisions, which are more complex than primary surgeries and result in
longer recovery time and much higher procedure costs [10]. In the 2018 International
Consensus Meeting (ICM) on musculoskeletal infection [10, 15], it has been concluded that
“Musculoskeletal infections remain the bane of orthopedic surgery, and result in grievous
illness and inordinate costs that threaten healthcare systems; … prevention, diagnosis, and
treatment has remained largely unchanged over the last 50 years” [10].
Patients who are diagnosed with PJI undergo revision surgery to replace an infected implant
with a new revision prosthesis. Revision surgery is challenging, and includes multiple stages
spanning several months. Revision surgery is also typically 5 to 10 times more expensive
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than the initial surgery, making PJI a significant burden for the health care system.
Additionally, most patients do not return to previous levels of activity after multiple revision
surgeries, and there is also a considerable drop in the patient's quality of life after infection
treatment and revision surgery due to PJI [16].
Total joint replacement implants are made mainly of bio-compatible, metal components
which carry a risk of foreign-body immune reaction near the prosthesis. Previous work in
animal models has shown that in the presence of a foreign body, the bacterial concentration
required to induce an infection is reduced by more than a factor of 100,000 [17], making the
risk of infection a very significant concern. Infection susceptibility is also dramatically
increased in the presence of a foreign body due to the establishment of a biofilm on the
foreign body surface that protects bacteria from host immune system defense [18]. This
protective environment makes PJI particularly tenacious and difficult to treat with systemic
antibiotics.
The current gold standard treatment for PJI is two-stage revision surgery: the first removes
the infected implant and treats infection; the second installs the final revision prosthesis.
During the first stage, following implant removal, a surgeon places temporary antibioticloaded cement spacer for local antibiotic delivery that targets the joint, in addition to
systemic infection treatment to ensure complete infection eradication. Unfortunately, the
mechanism of action for local antibiotic delivery is poorly characterized and local antibiotic
treatment is associated with relatively poor clinical outcomes. Elution of antimicrobial agents
through commonly employed carriers, such as Poly (methyl methaclyrate) (PMMA)
manifests as a rapid, initial diffusion phase, followed by a subsequent significant decrease.
This decrease may even lead to a drop in the antibiotic level below the bacterial minimum
inhibitory concentration (MIC), resulting in further bacterial resistance within the infected
joint, making treatment still more challenging. Current antibiotics carriers exhibit poor
diffusion characteristics. There is a distinct need to understand the diffusion mechanism
better and enhance infection treatment through local drug delivery in PJI.

3

1.1 Peri-Prosthetic Joint Infection
1.1.1 Definition
PJIs are classified as either chronic or acute. Acute PJI symptoms occur within 3-6 weeks
after primary joint replacements and are mainly due to direct contamination caused primarily
by highly virulent microorganisms [19]. Chronic PJI symptoms appear after six weeks
following primary joint replacement and are caused by low-virulence pathogens. There is
also a risk of late infection – more than two years after surgery – reported to be mainly due
to blood-borne dissemination [20]. Chronic and late infections are more challenging to
differentiate from mechanical loosening, since as the infection progress, it may produce
similar symptoms, such as implant loosening [9, 19].
The definition for PJI has dramatically improved diagnostic confidence among surgeons.
Musculoskeletal Infection Society (MSIS) has defined PJI as "a sinus tract (i.e., tunneling
wound) communicating with the prosthetic joint or two positive cultures with phenotypically
identical organisms from the peri-prosthetic tissue or fluid samples." Culture results may
also be supported by the presence of pre-operative and intra-operative minor criteria, such as:
elevated C-reactive protein (CPR); high synovial fluid white blood cell count; or positive
histological analysis of peri-prosthetic tissue [19, 20]. A further Consensus Meeting in 2013
endorsed the MSIS definition and modified it slightly to improve diagnostic confidence;
adding supportive evidence for absolute infection diagnosis and resulting in more accurate
guidelines for diagnosis. This includes developing a functional definition of “Acute” versus
“Chronic” PJI based on intra-operative findings (e.g., single culture growth, and positive
histology)[10]. Patients are classified as having a PJI if they meet the diagnostic criteria as
proposed by the MSIS and endorsed at the consensus meeting.

1.1.2 Risk Factors
PJI is most common in the first five years after primary joint replacement, however, it can
present at any time during the patient’s lifetime [10]. Many different risk factors are
associated with infected joints and increased short-term complications [10, 23]: patient age;
obesity, frailty, and smoking history, among others. Patients with a history of PJI or multiple
surgeries on the same joint should also be considered to be at high risk [21, 24]. Patients with
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symptoms such as continuous pain or stiffness in the revised joint may also represent a
higher probability of infection [21, 24]. In general, some modifiable risk factors make
patients more susceptible to developing PJI after primary joint replacement. A diagram
representing overall risk factors for joint infections was published by the American Academy
of Orthopedic Surgeons (AAOS) in 2009. (Fig 1.1)

Figure 1.1: Modifiable risk factors associated with peri-prosthetic joint infection. Patient
age, obesity, frailty, and smoking history, among other risk factors, have been associated with

increased short-term complications.
[Adapted from Orthopedic Infection prevention and control, AAOS 76 th meeting report, 2009].
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1.1.3 Diagnosis
Accurate and efficient diagnosis of PJI is a challenge for clinicians, and there is still no
absolute “gold-standard” available [9]. Significant evidence of PJI is identical, and
supportive evidence is often required [11]. PJI is typically diagnosed via a combination of
clinical, laboratory, and intraoperative findings. Imaging techniques can also be applied for
PJI diagnosis. While magnetic resonance imaging (MRI), computed tomography (CT), and
nuclear imaging are not considered direct approaches for PJI diagnosis, they can be used to
identify symptoms that are associated with infection in complicated cases [21]. Cyteval et al.
reported the application of CT to diagnose infection in hip, joint replacements. Some CT
findings, like peri-prosthetic fluid collection and joint distention, could be used to identify
PJI in the hip joint. Still, we may not be able to employ CT generally as a direct, diagnostic
tool for other joint infections [22]. MRI suffers from magnetic susceptibility artifacts near
metal implants, making PJI diagnosis challenging [23]. Among all imaging modalities,
nuclear medicine is often considered as a useful imaging technique for PJI diagnosis. This
imaging method has been used since the 1970s; however, these tests have limitations, in case
of sensitivity and accuracy. For example, bone scintigraphy is sensitive but not specific when
there are osseous abnormalities present. There is also typically a 1-3 day interval between
injection of the radiopharmaceutical and imaging [24].

1.1.4 Biofilms
The risk of infection in total joint replacements was described first by Gristina in 1987 [25].
Prosthetic implants will, ideally, function successfully for many years, making implant
surfaces potential interfaces on which individual bacteria can attach and eventually form a
biofilm, potentially resulting in PJI. The biofilm phenotype can describe chronic PJI. They
are mainly caused by the very rapid growth of bacteria [18]. Bacteria that are noted to cause
peri-prosthetic

infection

include

coagulase-negative

staphylococci

(30–43%),

Staphylococcus aureus (12–23%), streptococci (9–10%), enterococci (3–7%), gram-negative
organisms (3–6%) or anaerobes (2–4%) [26]. Staphylococci (specifically S. aureus and
Staphylococcus epidermis) are the most common biofilm-forming bacteria in PJI [27].
In biofilm formation, bacteria adhere to the implant surface in a highly hydrated extracellular
matrix. The microorganisms within biofilms form complex, highly organized communities
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[20] that are metabolically inactive and up to 1000 times more resistant to antibiotics than
systemic bacteria. Biofilms act as a protection layer against body immune response and
antibiotic penetration [28]. To completely eradicate biofilm-related bacteria, a much higher
concentration of antibiotics is required [29], making this problem notoriously tricky.
Concerns of systemic toxicity to the patient prevents clinicians from performing high-dose,
systemic antibacterial treatment. The most widely used antibiotics used in PJI are gentamicin,
tobramycin, and vancomycin [30].
Methicillin-resistant Staphylococcus aureus (MRSA) has been reported to play a vital role in
biofilm formation in peri-prosthetic joint infection [18]. The increasing prevalence of MRSA
in orthopedic infection makes current treatment even more complicated. MRSA bacteria
strains exhibit tolerance to antibiotics [18] by adhering to the implant, becoming sessile
(immobile), reducing their metabolic rate, and secreting a protein layer that protects them
from antibiotics. Biofilm-covered colonies then act as a reservoir for MRSA [31]. Moreover,
biofilms that are exposed to a level of antimicrobial agent below a certain concentration have
been shown to increase the development of biofilm formation and increase the likelihood of
further bacterial resistance [32]. This minimum inhibitory concentration (MIC) is defined as
the lowest concentration of antimicrobial agent that prevents bacteria growth [33]. There are
different methods available for measuring MICs of different microorganisms against
antimicrobial agents [34]. Thus, orthopedic implants exhibiting chronic infection caused by
MRSA must be removed. In a study of 117 patients with PJI, Cobo et al. [35] reported that
patients infected with MRSA had the highest rate of failure, even after two-stage revision
surgery. There is a high risk of infection recurrence after implanting the revision prosthesis,
if even a minimal amount of bacteria has been retained. Reducing the threat of antibioticresistant biofilms is a very active area of interest in recent years.

1.1.5 Treatment
Due to the projected burden of PJI to the health care system and individuals, an efficient and
safe strategy is required for treatment. Antibiotic therapy is a common general strategy to
treat chronic/acute PJI with a combination of surgical approaches. In acute PJI, clinicians
typically perform systemic antibiotic therapy and monitor the patients until the infection has
been eliminated, based on MSIS guidelines. The PJI patient then will undergo single surgery
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for debridement of necrotic and granulation tissue and exchange of the polyethylene spacer
in order to ensure that no bacteria remain in the infected joint. These approaches have been
reported to have a success rate that ranges between 31-78% [36].
For patients with chronic PJI, the current gold standard is two-stage revision surgery (Fig
1.2). In stage 1, the objective is to eradicate infection. Primary components are removed, and
patients undergo both systemic and local antibiotic therapy to ensure complete eradication of
infection. Clinicians typically take advantage of antibiotic carriers for local treatment,
combined with systemic therapy for 6-8 weeks, during which time patient serum
concentration is tracked to monitor infection level. After the infection is fully cleared, stage
2 is implemented to maintain joint biomechanics. During this surgery, temporary components
are removed, and a revision prosthesis is implanted after final debridement of surrounded
tissue.
Culture-directed intravenous (IV) antibiotics are commonly used for systemic therapy,
however, systemic treatment of infection with antibiotics should be limited to a certain level,
due to toxicity and potential damage to other body organs [31]. Systemic toxicity is a barrier
to performing high-dose systemic antibacterial treatment clinically. Reduced blood supply at
the site of infection also reduces the efficacy of systemic therapy [36]. Therefore, local drug
delivery is employed as an adjunct treatment to systemic therapy during Stage I.
Antimicrobial agents can be delivered locally to the surgical site via acrylic-based, nonbiodegradable cements (e.g., PMMA) or biodegradable, mineral-based bone cement (e.g.,
calcium sulfate or calcium phosphate). Local drug delivery also offers the potential for
controlled release over an extended time from novel release devices.
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Figure 1.2: Two-stage revision surgery in chronic PJI treatment. Stage 1 is to
eradicate infection; during Stage 1, the infected implant is removed, and local
antibiotic treatment is performed along with systemic therapy to eradicate infection.
Temporary antibiotic carriers are used at this stage for local treatment; after infection
is eliminated, temporary spacers are removed in Stage 2, and a new revision prosthesis
is implanted. (Adapted from Suhardi, Bichara et al. 2017)

1.2 Antibiotic Carriers
1.2.1 Poly methyl methacrylate (PMMA)
The use of PMMA as a bone cement spacer compound was first introduced by Buchholz
Engelbrecht for local drug delivery in PJI in 1970 [37]. Antimicrobial agents can be added to
temporary spacers during the industrial manufacture of the bone cement, or with manual
blending upon preparation within the operating room. Pre-mixed bone-cement spacers have
also been available since the 1990s [38]. Bone-cement spacers aim not only to deliver higher
dose antibiotic concentration to target tissue than systemic administration, but also to manage
and maintain the joint space after removal of the primary implant.
PMMA is an acrylic, dense, and non-absorbing material; although it is widely used in twostage revisions, there are several drawbacks associated with its application. It usually must be
removed in stage II of PJI treatment after fulfilling its function as a carrier for antibiotics and
a mechanical spacer within the joint [39]. If PMMA spacers remain for more extended
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periods without the placement of new revision implants, they have shown a complication rate
of 26–60 % within 49–54 months, mainly due to dislocation (11–17 %) and fracture (10–
14 %) [40]. PMMA also polymerizes during mixing of the powder polymer with a liquid
monomer and generates high temperature due to an exothermic reaction; thus, it is not an
ideal carrier choice for heat-sensitive antibiotics [39]. Moreover, due to poor mechanical
properties of PMMA, antibiotic concentration in these spacers is limited by the minimum
allowed mechanical properties. High-dose antibiotic-impregnated PMMA demonstrates an
increased risk of mechanical failure due to a drop in mechanical properties [41]. Hanssen et
al, classified antibiotic-loaded bone cement spacers into high dose (>2 g antibiotic per 40 g
cement) and low dose (<2 g antibiotic per 40 g cement) and recommended high dose for use
as beads in trauma-related infections and low dose for joint replacement prosthesis [42, 43].
Local treatment is an essential factor in infection eradication during stage I. PMMA exhibits
relatively poor antibiotic elution kinetics. In fact, it is likely that only 10% of the antibiotic is
eluted from PMMA bone cement due to its hydrophobicity [44]. Elution kinetics are often
defined as a ‘burst’ release of antibiotics over the first few days (7-10), followed by an
exponential drop over time [45]. This leads to the potential for sustained periods where local
antibiotic concentration falls below the MIC level [39]. Most studies agreed on a burst
release followed generally by an exponential decay in eluted antibiotic concentration from
PMMA carriers (i.e., biphasic release) [46-48]; thus, there is an absolute need for a new
approach to characterize antibiotic elution and develop materials and structures to deliver
high-dose antimicrobial agents consistently over a more extended period.

1.2.2 Calcium Sulphate and Calcium Phosphate
Calcium phosphate and calcium sulphate cement have been used for the treatment of bone
defects for more than one hundred years [49]. While PMMA bone-cement spacers are used
for high and medium load-bearing applications, calcium phosphate and calcium sulphate are
generally used for medium and low load-bearing applications. They are also a good choice
for drug delivery and are employed as antibiotic carriers in orthopaedic trauma infections
[49]. Whereas PMMA allows a small amount of antibiotic to release, these calcium-based
biomaterials eventually release their entire load of antibiotics due to their inherent
biodegradability [44]. They also provide much higher elution efficiency of antibiotics
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through diffusion. The elution is taking place over a more extended period, which may help
to maintain complete bacteria eradication during the intermediate stage of PJI treatment [30].
Calcium phosphate is usually a mix of two main components; one is the powder that is
basically a combination of different calcium phosphate salts, and two is the liquid, which is a
sodium phosphate solution. The paste would be prepared by mixing two components in the
operating room. The mixture would set in 2-7 minutes. After the paste hardens, it is very
similar to the mineral phase of the bone. Calcium phosphate will remain several years after
implantation, and its resorption rate is very slow. Unlike PMMA bone cement, calcium
phosphate is visible in x-ray images without any need to add contrast agents. Calcium
phosphate exhibits mechanical properties that range between cancellous and cortical bone in
compression (i.e., compression strength 17 MPa for calcium phosphate); however, it is lower
than cancellous bone in tensile and shear strength [49]. Unlike PMMA, polymerization of
calcium phosphate-based bone substitute is through hydration and generates a negligible heat
that does not denature incorporated heat-sensitive antibiotics [44].
Calcium sulphate bone substitutes are biocompatible and resorb much faster than calcium
phosphate, reported in the range of 40-70 days; however, the exact degradation rate depends
on the size and implanted location of the calcium sulphate. Rapid resorption of calcium
sulphate carriers increases the elution kinetics of antibiotics in local treatment. Resorption of
the carrier would make more space for antibiotic molecules to diffuse from the carrier to
target infected tissue, in other words, there are two mechanisms that combine to enhance
drug delivery in local treatment: small molecule diffusion (i.e., mass diffusion) and
resorption [49]. There are some other factors in vivo that might affect the entire diffusion
process (e.g., carrier swelling, chemical reactions, loads). During preparation of calcium
sulphate bone substitutes, powder and solution (which is mainly sterile water) are mixed and
the crystallization process starts; this process does not create any exothermic reaction. This is
an advantage over PMMA bone-cement carriers for the application of heat-sensitive
antibiotics. Calcium sulphate also has inherently high radiographic attenuation, and there is
no need to add any contrast agent. However, calcium sulphate has low mechanical strength; it
is weak and brittle, with low compressive strength.
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Although calcium sulphate carriers have been reported to exhibit superior elution
characteristics compared to PMMA, their poor mechanical properties act as a barrier for
application during an intermediate stage of PJI treatment as a replacement for current PMMA
carriers. Calcium sulphate occurs in the di-hydrate form naturally. The hemihydrate form is
produced by dehydration of the dihydrate by heating. There are two main compositions of
calcium sulphate material available, characterized as either an α-form or β-form hemihydrate,
depending on the method of heating. Conventional Plaster-of-Paris is the β-calcium sulphate
hemihydrate. The α-form provides a stronger product than the β-form, mainly due to
differences in the density [49]. High-purity, medical-grade, calcium sulphate (Stimulan®
Rapid Cure, Biocomposites, Keele, U.K.) is a synthetic, recrystallized α-hemihydrate [50].

1.3 Characterization of Antibiotic Elution
Although local antibiotic treatment is widely used as a standard method to eliminate infection
during the intermediate stage of PJI treatment, the exact mechanism of elution remains to be
fully elucidated. As discussed earlier, antimicrobial agents can be delivered to the surgical
site by temporary biocompatible carriers. These carriers can be either biodegradable or nonbiodegradable. PMMA bone cement and mineral-based bone substitutes (e.g., calcium
sulphate and/or phosphate) are two commonly available delivery carriers. These carriers are
routinely used to deliver antimicrobial agents to the target tissue and control infections
related to trauma or PJI. There are also some recent advances in developing polymer-based
biomaterials to be able to embed drug clusters in the polymer matrix. Drug-eluting polymers
might enhance local drug delivery due to higher elution characteristics over an extended
period, while maintaining mechanical strength to withstand loading [51, 52].
There is an undeniable demand to improve drug delivery in local treatment for ODRI. We
first need to understand the elution mechanisms of antibiotics in local treatment. Several
studies have focused on the characterization of antibiotic elution and their relative activity
against the most common bacteria that are associated with PJI (e.g., Staphylococcus aureus).
Release of antibiotic from a carrier depends on several factors such as carrier porosity,
antibiotic types and combinations, corresponding concentration ratio (i.e., loading amount),
carrier preparation techniques, carrier surface characteristics, dynamic or static environment,
and also in-vivo circumstances, such as the effect of exposure to body fluids [48, 52].
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A literature search was performed through PubMed to update our knowledge regarding
methods that have been introduced to study elution characteristics of antibiotics in local
treatment of ODRI. We can classify available literature into in-vitro and in-vivo studies. Invitro characterization of elution is based on measuring local antibiotic concentration in a
culture medium (e.g., normal saline, phosphate-buffered saline (PBS), simulated body fluid)
at various time points. The common methodology of in-vitro evaluation of elution
characteristics is based on incorporating a known concentration of antimicrobial agents to a
defined carrier, immersing the carrier in a solution, and finally, invasive-sampling of the
solution at various time points to measure antibiotic concentration available within the
solution. The antimicrobial agent concentration that is available in the solution at different
time points is then used to describe the diffusion characteristic of that agent through the
known carrier [39, 45, 53]. The amount of the solution in which antimicrobial agent is
diffusing should be maintained at a level for invasive sampling, while ensuring full coverage
of the antibiotic-loaded carriers; thus, the medium needs to be refreshed totally or partially
after invasive-sampling at each time point. In this way, invasive sampling may affect the
diffusion kinetics. The concentration of antimicrobial agents within the medium can also be
measured by the application of different methods such as ultraviolet (UV) high-performance
liquid chromatography (HPLC), UV spectroscopy, combined liquid chromatography-mass
spectrometry (LC-MS), fluorescence polarization immunoassay, and a flow chamber
technique for medium collection and disk diffusion assay [39, 45, 54-58].
There are some other methodologies described in the literature to study antibiotic elution.
Merkhan et al. developed a technique to evaluate antibiotic concentration in PBS by
measuring the relative pH. He hypothesized that the pH of the PBS medium is a function of
antibiotic concentration that has been diffused into the solution. This study evaluated the
release kinetics of gentamicin from PMMA cement [59].
Evaluating the zone of inhibition (ZOI) is another method to describe antibiotic elution
characteristics seen in the literature. ZOI is defined as a circular area around the spot of the
antibiotic in which the bacteria colonies do not grow. Although ZOI is mainly used to
maintain the bioactivity of bacteria against different types and concentrations of
antimicrobial agents, it can also be used to quantify the elution kinetics of antibiotics. For this
methodology, a plate of medium is first seeded by known bacteria, and antibiotic-

13

impregnated carriers would then be placed on the plate. The plate can be assessed to evaluate
the clearance zone around the carriers over time. The measurement of ZOI at various time
points will represent how far antibiotics have been released [60] and so can be used to
compare the diffusion rate within different carriers.
Along with molecular diffusion that is based on random motion of the molecules from a
higher gradient to lower gradient levels, some other factors affect the elution characteristics
from a specific carrier in-vivo. Rogers et al. reported the effect of loads on diffusion
characteristics. They measured the antibiotic diffusion from PMMA knee spacers in
phosphate buffer saline after performing cyclic loading on the phantom. They concluded that
dynamic spacers would have a higher elution rate than static spacers, and loading will
promote elution characteristics [61].
Kummer et al. described the effect of sonication on elution kinetics. They presented that
PMMA has higher elution kinetics when combined with sonication over a particular period
of time. However, the application of sonication to enhance elution from calcium
sulphate/phosphate carriers remains unclear [62].
One drawback of the above methodologies is the invasive sampling of the medium. As
described, a sample from a medium (i.e., the solution in which antimicrobial agent is
diffusing) is invasively collected at each time point. The concentration of the antimicrobial
agent then measured within the collected sample to describe the diffusion of the
antimicrobial agent. Antimicrobial-loaded carriers can also be washed out thoroughly and
placed in a new fresh solution for the next time point sample collection. However, in the invivo environment, diffusion of the antimicrobial agent into the surrounding tissues is
occurring in a diffusion-limited environment. There is some evidence that if we expose the
antimicrobial-loaded carrier into fresh fluids, the elution kinetics may vary. Elution may
cause a saturation of the surrounding medium in a controlled environment, and the gradient
that supports the antimicrobial agent release at the beginning is expected to drop faster over
time in the case of saturation [52, 63].
Dusane et al. studied the diffusion of antibiotic from PMMA and calcium sulphate carriers
by using a diffusion-limited agar method to simulate in-vivo controlled environment. In this
study, carriers were created and embedded in pure agar to track diffusion into a finite agar
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sink (i.e., a reservoir that molecules can diffuse from the core into it). The agar gel diffusion
method was used to evaluate bacteria bioactivity by measuring the ZOI over different time
points [60]. A second study was performed by using a fluorescein optical tracer as a surrogate
for antibiotics [47]. In this study, researchers loaded fluorescein tracer into the carriers as a
surrogate for commonly available antibiotics. Fluorescein dye tracer is a freely water-soluble
material that shows hydrophilic characteristics and can be used as a surrogate for antibiotics
in order to study elution kinetics [64-66]. Fluorescent optical imaging techniques were used
to monitor release kinetics and track the diffusion distance of fluorescein over time. Realtime images were taken by a gel documentation system, and the diffusion distance was
observed in a solid hydrogel agar medium and calculated by standard image thresholding.
The release of antibiotics from actual-size knee and hip PMMA cement spacers has also been
studied in vivo. These studies were performed either during the intermediate stage of PJI
treatment (when a temporary spacer is implanted) or after removal of the spacer. Measuring a
patient's serum antibiotic concentration over time was used to evaluate elution kinetics [67].
Pharmacokinetic properties in vivo at the time of spacer implantation was also determined by
collecting synovial fluid from patients. The final concentration of antibiotics was obtained
from the fluid joint at the time of spacer removal during intermediate stage surgery [52].

1.4 Thesis Objectives
The overall goal of this work is to characterize and improve local drug delivery in PJI
management. Although local antibiotic delivery is commonly used in PJI treatment, the exact
diffusion mechanism is not fully understood. There is an obvious need to better understand
antibiotic diffusion in local drug delivery, and subsequently deliver high dose antibiotics to
the target tissue with the desired diffusion rate over an extended period (while maintaining
necessary mechanical properties).
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The specific objectives of this work are:
1. Development

of

a quantitative, non-invasive, longitudinal

micro-computed

tomography (micro-CT) imaging technique to characterize the diffusion of small
molecules from a finite-source carrier to a finite tissue-equivalent phantom sink.
2. Design and fabrication of a 3D-printed metal porous scaffold and investigation of the
application of highly porous structures in the development of drug-delivery systems.
A highly porous metal scaffold can separate the competing needs for mechanical
strength by providing structural support while maintaining appropriate drug-elution
characteristics.

1.5 Scope of Thesis
Chapter 2: quantitative, non-invasive micro-CT imaging technique to characterize smallmolecule diffusion.
Given the introduction to PJI, current standard treatment, and previous literature, there is
considerable evidence that the exact antibiotic elution mechanism from bone cement spacers
is not yet well understood. We believe that a new approach is required in order to make
significant progress in local drug delivery in PJI treatment. A micro-CT imaging technique
can be used to characterize small-molecule diffusion. In this chapter, we demonstrate the
development of a non-destructive, non-invasive, longitudinal image-based method to track
the diffusion of a drug surrogate contrast agent over time. The concept of using drug
surrogate is not new; fluorescein has been used as an optical tracer to study elution in
calcium sulphate and PMMA previously [47]. However, in this research, we use an x-ray
contrast agent (Iohexol) with a molecular weight of 821 Da, which is much closer to that of
commonly used antibiotics like Vancomycin with a molecular weight of 1449 Da compared
to fluorescein with molecular weight of 332 Da.
Chapter3: mechanical properties and diffusion characterization of highly porous 3D-printed
scaffolds
In this chapter, we aim to design and fabricate a 3D-printed titanium-alloy porous structure
and investigate the concept of a highly-porous metal scaffold containing antibiotic-eluting
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carriers. Our structure aims to deliver high-dose antibiotics with calcium-sulphate carriers.
Calcium sulphate carriers provide superior elution kinetics compare to PMMA, and the
proposed porous structure would maintain the necessary mechanical properties.
We based our scaffold design on a gyroid-based structure. The gyroid provides the advantage
of a highly porous, open structure without significant stress concentrations [68]. Gyroid
parameters (i.e., unit-cell size and wall thickness) can be modified parametrically, providing
control over the porosity and hence mechanical strength. We modified the parameters for the
gyroid-based design over the range of 60 to 90% porosity; these values fall within the range
that can be fabricated in metal using 3D printing. Cylindrical gyroid-based scaffolds with
80% porosity were selected to perform a diffusion experiment and characterize the diffusion
of Iohexol contrast agent drug-surrogate using micro-CT within the presence of the metal
scaffold. The long-term goal in this work is to develop more effective drug-eluting implants,
potentially removing the need for two-stage revision surgery.

17

1.6 References
1.

Qiu, X.S., et al., Coating the plate with antibiotic cement to treat early infection after
fracture fixation with retention of the implants: a technical note. BMC Musculoskelet
Disord, 2018. 19(1): p. 360.

2.

Moriarty, T.F., et al., Orthopaedic device-related infection: current and future
interventions for improved prevention and treatment. EFORT Open Rev, 2016. 1(4):
p. 89-99.

3.

Metsemakers, W.J., et al., Influence of implant properties and local delivery systems
on the outcome in operative fracture care. Injury, 2016. 47(3): p. 595-604.

4.

Raschke, M., T. Vordemvenne, and T. Fuchs, Limb salvage or amputation? The use
of a gentamicin coated nail in a severe, grade IIIc tibia fracture. Eur J Trauma Emerg
Surg, 2010. 36(6): p. 605-8.

5.

Hutzler, L. and J. Williams, Decreasing the Incidence of Surgical Site Infections
Following Joint Replacement Surgery. Bull Hosp Jt Dis (2013), 2017. 75(4): p. 268273.

6.

Kamath, A.F., et al., Quantifying the Burden of Revision Total Joint Arthroplasty for
Periprosthetic Infection. J Arthroplasty, 2015. 30(9): p. 1492-7.

7.

Kurtz, S.M., et al., Economic burden of periprosthetic joint infection in the United
States. J Arthroplasty, 2012. 27(8 Suppl): p. 61-5 e1.

8.

Bhandari, M., et al., Clinical and economic burden of revision knee arthroplasty. Clin
Med Insights Arthritis Musculoskelet Disord, 2012. 5: p. 89-94.

9.

Boddapati, V., et al., Revision Total Knee Arthroplasty for Periprosthetic Joint
Infection Is Associated With Increased Postoperative Morbidity and Mortality
Relative to Noninfectious Revisions. J Arthroplasty, 2018. 33(2): p. 521-526.

10.

Hip and Knee Replacements in Canada, 2017 - 2018. Canadian Joint Replacement
Registry Annual Report, 2019. Canadian Institute for Health Information.

11.

Morgenstern, M., et al., Diagnostic challenges and future perspectives in fracturerelated infection. Injury, 2018. 49: p. S83-S90.

12.

Shohat, N. and J. Parvizi, Prevention of Periprosthetic Joint Infection: Examining the
Recent Guidelines. J Arthroplasty, 2017. 32(7): p. 2040-2046.

13.

AJRR Annual Report on Hip and Knee Arthoplasty Data. American Joint
Replacement Registry, 2019: p. 60.

18

14.

Shahi, A., et al., In-Hospital Mortality in Patients With Periprosthetic Joint Infection.
J Arthroplasty, 2017. 32(3): p. 948-952 e1.

15.

Saeed, K., et al., 2018 international consensus meeting on musculoskeletal infection:
Summary from the biofilm workgroup and consensus on biofilm related
musculoskeletal infections. J Orthop Res, 2019. 37(5): p. 1007-1017.

16.

Morgenstern, M., et al., The effect of local antibiotic prophylaxis when treating open
limb fractures: A systematic review and meta-analysis. Bone Joint Res, 2018. 7(7): p.
447-456.

17.

Kapadia, B.H., et al., Periprosthetic joint infection. The Lancet, 2016. 387(10016): p.
386-394.

18.

McConoughey, S.J., et al., Biofilms in periprosthetic orthopedic infections. Future
Microbiol, 2014. 9(8): p. 987-1007.

19.

Parvizi, J., et al., The 2018 Definition of Periprosthetic Hip and Knee Infection: An
Evidence-Based and Validated Criteria. J Arthroplasty, 2018. 33(5): p. 1309-1314 e2.

20.

Cyteval, C. and A. Bourdon, Imaging orthopedic implant infections. Diagn Interv
Imaging, 2012. 93(6): p. 547-57.

21.

Zmistowski, B., et al., Diagnosis of periprosthetic joint infection. J Arthroplasty,
2014. 29(2 Suppl): p. 77-83.

22.

Cyteval, C., et al., Painful infection at the site of hip prosthesis: CT imaging.
Radiology, 2002. 224(2): p. 477-83.

23.

Love, C., et al., Role of nuclear medicine in diagnosis of the infected joint
replacement. Radiographics, 2001. 21(5): p. 1229-38.

24.

Love, C. and C.J. Palestro, Nuclear medicine imaging of bone infections. Clin Radiol,
2016. 71(7): p. 632-46.

25.

Gristina, A.G., Biomaterial-centered infection: microbial adhesion versus tissue
integration. Science, 1987. 237(4822): p. 1588-95.

26.

Pandey, R., A.R. Berendt, and N.A. Athanasou, Histological and microbiological
findings in non-infected and infected revision arthroplasty tissues. The OSIRIS
Collaborative Study Group. Oxford Skeletal Infection Research and Intervention
Service. Arch Orthop Trauma Surg, 2000. 120(10): p. 570-4.

27.

Choong, P.F., et al., Risk factors associated with acute hip prosthetic joint infections
and outcome of treatment with a rifampinbased regimen. Acta Orthop, 2007. 78(6): p.
755-65.

28.

Giulieri, S.G., et al., Management of infection associated with total hip arthroplasty
according to a treatment algorithm. Infection, 2004. 32(4): p. 222-8.

19

29.

Smith, A.W., Biofilms and antibiotic therapy: is there a role for combating bacterial
resistance by the use of novel drug delivery systems? Adv Drug Deliv Rev, 2005.
57(10): p. 1539-50.

30.

Sasaki, T., et al., In vitro elution of vancomycin from calcium phosphate cement. J
Arthroplasty, 2005. 20(8): p. 1055-9.

31.

Patel, A., et al., Methicillin-resistant Staphylococcus aureus in orthopaedic surgery. J
Bone Joint Surg Br, 2008. 90(11): p. 1401-6.

32.

Jefferson, K.K., D.A. Goldmann, and G.B. Pier, Use of confocal microscopy to
analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms.
Antimicrob Agents Chemother, 2005. 49(6): p. 2467-73.

33.

Andrews, J.M., Determination of minimum inhibitory concentrations. J Antimicrob
Chemother, 2001. 48 Suppl 1: p. 5-16.

34.

Schumacher, A., et al., In vitro antimicrobial susceptibility testing methods: agar
dilution to 3D tissue-engineered models. Eur J Clin Microbiol Infect Dis, 2018. 37(2):
p. 187-208.

35.

Cobo, J., et al., Early prosthetic joint infection: outcomes with debridement and
implant retention followed by antibiotic therapy. Clin Microbiol Infect, 2011. 17(11):
p. 1632-7.

36.

Kuiper, J.W., et al., Treatment of acute periprosthetic infections with prosthesis
retention: Review of current concepts. World J Orthop, 2014. 5(5): p. 667-76.

37.

Buchholz, H.W. and H. Engelbrecht, [Depot effects of various antibiotics mixed with
Palacos resins]. Chirurg, 1970. 41(11): p. 511-5.

38.

Boelch, S.P., et al., Loading with vancomycin does not decrease gentamicin elution in
gentamicin premixed bone cement. J Mater Sci Mater Med, 2017. 28(7): p. 104.

39.

Aiken, S.S., et al., Local release of antibiotics for surgical site infection management
using high-purity calcium sulfate: an in vitro elution study. Surg Infect (Larchmt),
2015. 16(1): p. 54-61.

40.

Jung, J., et al., Complications after spacer implantation in the treatment of hip joint
infections. Int J Med Sci, 2009. 6(5): p. 265-73.

41.

Lilikakis, A. and M.P. Sutcliffe, The effect of vancomycin addition to the compression
strength of antibiotic-loaded bone cements. Int Orthop, 2009. 33(3): p. 815-9.

42.

Hanssen, A.D., Prophylactic use of antibiotic bone cement: an emerging standard--in
opposition. J Arthroplasty, 2004. 19(4 Suppl 1): p. 73-7.

20

43.

Hanssen, A.D. and M.J. Spangehl, Practical applications of antibiotic-loaded bone
cement for treatment of infected joint replacements. Clin Orthop Relat Res,
2004(427): p. 79-85.

44.

Urabe, K., et al., In vitro comparison of elution characteristics of vancomycin from
calcium phosphate cement and polymethylmethacrylate. J Orthop Sci, 2009. 14(6): p.
784-93.

45.

Samuel, S., et al., In vitro study of elution kinetics and bio-activity of meropenemloaded acrylic bone cement. J Orthop Traumatol, 2012. 13(3): p. 131-6.

46.

Tsiapla, A.R., et al., Drug delivery nanoplatform for orthopaedic-associated
infections. Materials Today: Proceedings, 2017. 4(7): p. 6880-6888.

47.

Dusane, D.H., et al., Effects of loading concentration, blood and synovial fluid on
antibiotic release and anti-biofilm activity of bone cement beads. J Control Release,
2017. 248: p. 24-32.

48.

Bishop, A.R., et al., Vancomycin elution, activity and impact on mechanical
properties when added to orthopedic bone cement. J Mech Behav Biomed Mater,
2018. 87: p. 80-86.

49.

Larsson, S., Injectable Phosphate Cements - A Review. Uppsala, Sweden, 2006. 2006.

50.

Oliver, R.A., et al., Application of Calcium Sulfate for Dead Space Management in
Soft Tissue: Characterisation of a Novel In Vivo Response. Biomed Res Int, 2018.
2018: p. 8065141.

51.

Kim, T.W.B., et al., 3D printed liner for treatment of periprosthetic joint infections.
Med Hypotheses, 2017. 102: p. 65-68.

52.

Anagnostakos, K. and C. Meyer, Antibiotic Elution from Hip and Knee Acrylic Bone
Cement Spacers: A Systematic Review. Biomed Res Int, 2017. 2017: p. 4657874.

53.

Cao, Z., et al., In vitro and in vivo drug release and antibacterial properties of the
novel vancomycin-loaded bone-like hydroxyapatite/poly amino acid scaffold. Int J
Nanomedicine, 2017. 12: p. 1841-1851.

54.

Bakhshandeh, S., et al., Simultaneous Delivery of Multiple Antibacterial Agents from
Additively Manufactured Porous Biomaterials to Fully Eradicate Planktonic and
Adherent Staphylococcus aureus. ACS Appl Mater Interfaces, 2017. 9(31): p. 2569125699.

55.

Hernandez-Soria, A., et al., In vitro elution characteristics of antibiotic laden
BoneSource, hydroxyapatite bone cement. J Biomater Sci Polym Ed, 2013. 24(7): p.
797-806.

56.

Suhardi, V.J., et al., A Fully Functional Drug-Eluting Joint Implant. Nat Biomed Eng,
2017. 1.

21

57.

Houdek, M.T., et al., Elution of High Dose Amphotericin B Deoxycholate From
Polymethylmethacrylate. J Arthroplasty, 2015. 30(12): p. 2308-10.

58.

Stevens, C.M., et al., An articulated antibiotic spacer used for infected total knee
arthroplasty: a comparative in vitro elution study of Simplex and Palacos bone
cements. J Orthop Res, 2005. 23(1): p. 27-33.

59.

Merkhan, I.K., J.M. Hasenwinkel, and J.L. Gilbert, Gentamicin release from twosolution and powder-liquid poly(methyl methacrylate)-based bone cements by using
novel pH method. J Biomed Mater Res A, 2004. 69(3): p. 577-83.

60.

McConoughey, S.J., et al., Comparing PMMA and calcium sulfate as carriers for the
local delivery of antibiotics to infected surgical sites. J Biomed Mater Res B Appl
Biomater, 2015. 103(4): p. 870-7.

61.

Rogers, B.A., et al., Does cyclical loading affect the elution of antibiotics from
articulating cement knee spacers? J Bone Joint Surg Br, 2011. 93(7): p. 914-20.

62.

Kummer, A., U.F. Tafin, and O. Borens, Effect of Sonication on the Elution of
Antibiotics from Polymethyl Methacrylate (PMMA). J Bone Jt Infect, 2017. 2(4): p.
208-212.

63.

Kelm, J., et al., In vivo and in vitro studies of antibiotic release from and bacterial
growth inhibition by antibiotic-impregnated polymethylmethacrylate hip spacers.
Antimicrob Agents Chemother, 2006. 50(1): p. 332-5.

64.

Seidlitz, A., et al., In vitro determination of drug transfer from drug-coated balloons.
PLoS One, 2013. 8(12): p. e83992.

65.

van Oosten, M., et al., Real-time in vivo imaging of invasive- and biomaterialassociated bacterial infections using fluorescently labelled vancomycin. Nat
Commun, 2013. 4: p. 2584.

66.

Stone, M.R.L., et al., Fluorescent Antibiotics: New Research Tools to Fight Antibiotic
Resistance. Trends Biotechnol, 2018. 36(5): p. 523-536.

67.

Liu, S.J., et al., In vivo release of vancomycin from biodegradable beads. J Biomed
Mater Res, 2002. 63(6): p. 807-13.

68.

Kelly, C.N., et al., Fatigue behavior of As-built selective laser melted titanium
scaffolds with sheet-based gyroid microarchitecture for bone tissue engineering. Acta
Biomater, 2019. 94: p. 610-626.

22

Chapter 2
2

Quantitative, non-invasive micro-CT imaging technique to
characterize small-molecule diffusion

We have developed a quantitative, non-invasive, longitudinal, micro-CT imaging technique
to characterize the diffusion of a small-molecule drug surrogate within an intact, agar tissueequivalent phantom. Iohexol, an iodine-based x-ray contrast agent, was selected as a drug
surrogate to estimate the relative diffusion behavior of a commonly used antibiotic (i.e.,
Vancomycin) within three different carriers. A concentration of Iohexol was selected that
maintains appropriate image contrast during the series of longitudinal scans to effectively
monitor diffusion, and with sufficiently low beam-hardening effects that could be corrected
within each experiment.
The short-term and long-term release of the drug surrogate was observed in a two-part
phantom consisting of a cylindrical, finite-source “core” containing the drug surrogate, and a
surrounding agar, tissue-equivalent “sink” into which the drug surrogate diffuses. The
phantom core was created by mixing the Iohexol contrast agent drug surrogate into a carrier
material – either one of two calcium sulphate-based (CaSO4) matrices or pure agar – for
different experiments. Diffusion of the drug surrogate into the surrounding tissue-mimic was
observed by monitoring the image signal intensity as the contrast-agent progresses outward
from the cylindrical, finite-source core during longitudinal scanning. It was assumed that the
contrast agent is more or less homogeneously distributed throughout the carrier, forming a
monolithic solution. In this chapter, the experimental design of the diffusion phantom is
explained in detail, along with micro-CT image acquisition parameters selected for the
purpose of this work. Images were corrected for beam-hardening “cupping” artifact that
would affect the apparent relative diffusion of the contrast agent.

Image analysis was

performed to assess contrast-agent (i.e., drug surrogate) concentration and track radialdiffusion distance for the duration of the longitudinal scanning. The diffusion coefficient of
the drug-surrogate contrast agent through our carrier materials was then calculated, based on
available mathematical models of diffusion [1-3].
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2.1 Introduction
Peri-prosthetic joint infection (PJI) has been receiving a high level of attention in recent years
[4]; as described in Chapter 1, it is a serious complication resulting in prolonged treatment
and morbidity [5]. To eliminate the infection in a clinical environment, systemic treatment is
performed along with local antibiotic delivery. Current delivery methods are by incorporating
commonly used antibiotics (e.g., Vancomycin, Tobramycin, Gentamycin) in a matrix carrier
to form a drug delivery system. Carriers are then implanted into the joint space temporarily
to elute antibiotics. In-vitro studies demonstrate that calcium sulfate-based carriers (e.g.,
Stimulan® Rapid Cure) may improve the elution of antibiotics (i.e., Vancomycin) compared
to commonly used Poly (methyl methacrylate) (PMMA) carriers [6].
Although local antibiotic delivery is widely used in PJI management, the exact diffusion
mechanism remains elusive to the extent of our knowledge. Thus, a new approach is required
to better understand and enhance antibiotic elution through finite-source, local drug-delivery
carriers. There are complications associated with in-vivo tracking of drug diffusion and
release amount due to biological factors and chemical reactions. Different types of mass
transport processes can be involved in vivo in the control of drug release from a carrier. This
might include the penetration of water into the system ( osmotic effects), drug diffusion from
the carrier, drug dissolution, carrier swelling, carrier erosion, and various other phenomena
[1]; however, “ if several of these processes occur in a sequence and one is much slower than
all the other, the slowest one is the rate-limiting step for the entire sequence” [1]. In many
cases, drug diffusion is the predominant step, however, in some others, it plays a major role
in combination with carrier swelling or degradation [1]; in this study, we focused on mass
diffusion controlled drug-delivery systems. For the system to be diffusion controlled, the rate
of dissolution of drug particles within the matrix carrier is assumed to be much faster than the
diffusion rate of the dissolved drug leaving the carrier [7]. Some carriers have a very high
rate of resorption in vivo (i.e., calcium sulphate carriers that resorb within 40-70 days after
implantation), which affects the effective elution of small-molecules. In this work, we
evaluate the diffusion of an Iohexol-based contrast agent as a drug-surrogate only through
mass diffusion.
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Drug diffusion (e.g., antibiotics) from a carrier (i.e., PMMA and mineral based bone
substitutes) has been studied in vitro in PJI management by application of chemical analysis
such as chromatography and spectroscopy [8-11]. While such studies have yielded valuable
information, they provide little understanding of drug diffusion distance from a finite source
into a finite environment that is similar to in-vivo conditions. These methods also limit realtime, non-invasive tracking of diffusion, which could provide quantitative information in
future studies of drug diffusion in live animals.
Imaging can be a non-invasive longitudinal technique to track the diffusion of small
molecules over time from a finite source to a finite environment in an intact phantom. The
concept of tracking a surrogate molecule has been reported previously. Fluorescein
(molecular weight 332 Da) was used as an optical tracer to study elution in calcium-sulfate
based carriers and Poly (methyl methacrylate) (PMMA) [12]. Our approach instead uses an
X-ray contrast agent (iodine-based Iohexol), with a molecular weight of 821 Dalton (Da),
which is much closer to that of commonly used antibiotics, like Vancomycin (molecular
weight 1449 Da), to track diffusion in a tissue-equivalent agar sink.
The purpose of this chapter is to characterize the diffusion of a small molecule drug surrogate
from calcium-sulphate and agar-based carriers into an agar tissue-equivalent sink. This
objective has been accomplished by developing a novel method for image-based
quantification of small-molecule diffusion; we use a micro-CT imaging technique to collect
the attenuation of a high-atomic number contrast agent drug surrogate (iodine-based Iohexol)
over regular time intervals. Corresponding CT numbers are correlated to the concentration of
contrast agent drug surrogate within the voxels; this will allow us to track the diffusion
distance and the cumulative amount released from the finite-source over time. The diffusion
coefficient was then calculated by using the acquired data set from volumetric images and
implementing previously described mathematical diffusion models.

2.1.1 Micro-CT Imaging
Within this work, our interest is placed on the use of a micro-CT imaging technique to
monitor and quantify the diffusion of a contrast agent drug surrogate into an agar sink, using
a tissue-equivalent phantom. Here, the micro-CT imaging approach will be described, along
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with the specification of the system selected to monitor the diffusion and subsequent relative
features for our experiments.
Wilhelm Conrad Röntgen first announced the discovery of X-rays in 1895 [13]. Planar x-ray
imaging is the earliest medical imaging modality that was clinically used before the
development of the CT imaging technique. X-ray imaging techniques are based on creating
an image by irradiating the specimen of interest. In planar X-ray imaging, the image that is
created is a single X-ray projection of the specimen. The X-ray source transmits a beam of
photons to irradiate the specimen. The intensity of the X-ray beam is attenuated through the
specimen along paths of known geometry. Attenuation is a result of X-ray photon
interactions with the atoms and orbital electrons within the specimen, which can be either via
absorption or scattering; the attenuation coefficient describes the amount of attenuation. A
detector is then placed opposite the X-ray source to collect and measure the intensity of
attenuated X-ray beams to create an image [14].
Computed tomography (CT) imaging is also an X-ray-based imaging technique. It combines
X-ray transmission with computed tomographic reconstruction to make three-dimensional
(3D) image volumes. The image that is created consists of a 3D array of volume elements
(i.e., voxels, or 3D pixels) that represent the radio density, or mean linear X-ray attenuation
of the material contained within each individual voxel. Unlike planar x-ray images that
represent the total attenuation of the X-rays along a line passing through the complete
specimen, images in clinical computed tomography (CT) are created with a fan-shaped x-ray
beam that rotates around the object while it moves through the gantry. The x-ray source and
detector are mounted onto a rotating gantry, which allows the acquisition of x-ray projections
over 360° around the object.
CT numbers are used to quantify the differences in X-ray attenuation occurring in a voxel.
Attenuation values are typically scaled to Hounsfield units (HU) [15]. Values are based on
the tissue electron densities and level of photon absorption. Air and water are arbitrarily
assigned the values of -1000 HU and 0 HU, respectively, and are commonly used for
calibration purposes [16]. In clinical applications, the best-visualized tissues with the most
significant contrast in X-ray images are highly attenuating tissues (such as bone) and least
attenuating tissue (such as an air-filled lung). The differences in X-ray attenuation are
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determined by the object’s electron density and physical density in each projection image.
Attenuation, therefore, leads to image contrast in X-ray imaging. Hounsfield and Cormack
were awarded the Nobel Prize in medicine (1979) for the invention of CT imaging [15, 17].
Cone-beam CT is based on the same principles as a conventional CT scanner but with the
advantages of faster acquisition and (typically) higher resolution [18]. There is a coneshaped X-ray beam (i.e., fan in two directions) with a rotating flat-panel area detector (Fig
2.1). Transmission data is collected by an area detector, rather than multiple rows of
detectors, allowing a fast scan of the entire organ in the body in clinical application. The
rotating-gantry configuration is the most common configuration for cone-beam CT scanners;
this design mounts the tube and detector on a gantry that rotates around a central axis [18].
The rotating object is another less common design of cone-beam CT scanners. Cone-beam
back-projection reconstruction algorithms that account for geometry and ray path than are
used to reconstruct a volumetric image from two-dimensional (2D) image projections. The
duration of the collection of projections depends on the flux of photons being produced by
the X-ray source, the efficiency of the X-ray detector, and the amount of attenuation of the
photons by the scanned material. It is possible to make trade-offs in the system to collect
scans faster or slower, with associated impacts on the image quality.
Micro-computed tomography (micro-CT) functions in the same manner as clinical CT
scanners, but provides higher reconstruction resolution. Moreover, micro-CT scanners create
images with isotropic voxels, and there is a consistent resolution in all planes. Typical
scanners are available with voxel sizes ranging from 5 to 450 μm and fields of view ranging
from 1 to 20 cm [19]. Micro-CT has developed into a popular research tool in small-animal
and phantom experiments since it provides finer isotropic resolution [20]. Micro-CT has also
been shown to have the capability of providing advanced analytical techniques and detailed
internal quantitative information to investigate drug delivery [21, 22].
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Figure 2.1: Principle of cone-beam CT scanner. Object is irradiated by the X-ray
beam and the attenuated X-rays are collected by a flat panel detector, providing a single
two-dimensional projection. The gantry rotates by a small defined increment angle; at

the next angular position another projection is acquired. Subsequently numerous 2D
projections are collected over various angles around the object to construct a
volumetric image.
(adapted from cone beam computed tomography by William C.Scarfe and Allan G. Farman, chapter 11)

Laboratory micro-CT scanners (e.g., the GE eXplore speCZT located at the Robarts Research
Institute, Fig 2.2) consist of a cone-beam X-ray source and 2D flat panel detector, which
provides a collection of multiple paths of attenuation simultaneously. This pre-clinical microCT system has a high resolution (i.e., 50 µm) combined with fast scanning speed. An area
detector mounted on a gantry allows the X-ray source and detector to rotate around the
phantom and collect individual 2D projections at different angles in a relatively short time
(typically 5 minutes per volume). After collection of a series of 2D images, it is necessary to
reconstruct the 3D volume. The 2D projection are convolved with proper Kernel function to
reduce blur and then back-projected into the 3D space to create the final image. The
reconstructed images are comprised of a 3D matrix of voxels, with each voxel containing a
CT number, which is proportional to the mean linear attenuation coefficient of the material
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within that voxel. The intensity of each voxel is then measured and rescaled in Hounsfield
units.
In this work, we investigate the application of a micro-CT imaging technique to characterize
the diffusion of a contrast-agent drug surrogate. An image-based technique to characterize
diffusion has the advantage of tracking diffusion mechanisms non-invasively and without
sample collection, also providing real-time characterization of diffusion. In this work, a radio
opaque contrast agent with high atomic number and density was chosen to be used as a
surrogate for commonly used antibiotics (i.e., Vancomycin) to evaluate diffusion in an agar
tissue-equivalent phantom. Cumulative release amount was measured by taking advantage of
the relationship between CT number and contrast-agent concentration in acquired volumetric
images [23, 24] and the law of mass conservation. The technique described in this chapter
allows non-invasive, non-destructive analysis of contrast-agent drug-surrogate diffusion over
an extended time in an intact phantom. This approach will simulate mass-diffusion controlled
delivery systems and is used to compare the diffusion behaviour of one drug-surrogate (i.e.,
iodine-based Iohexol) out of different carrier matrices into an agar sink.

Figure 2.2: GE eXplore speCZT. Located at Robarts Research Institute, it is a conebeam micro-CT imaging system, which we used in this work to characterize diffusion
of a contrast-agent drug surrogate (Iohexol).
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2.1.2 Beam Hardening
CT scanners use polychromatic x-ray beams which can be characterized by the peak energy.
For example, in this study, we scanned our phantom at a tube voltage of 90 kVp; it means
that our photons have energy ranging from 20 – 90 keV. In imaging different materials, lowenergy photons mainly absorb by photoelectric absorption (Grodstein, 1957); the mean
energy of remaining photons increases, and this results in the transmitted spectrum becoming
"harder." Beam hardening causes an artifact in CT reconstructed volumetric images. In
other words, there would be an overestimate in photon transmission, which leads to
underestimating the attenuation coefficient of materials [25]. The center of an object will
exhibit lower CT numbers than the edges in a homogeneous material, which is described as a
"cupping" artifact (Fig 2.3). The higher the density of the material, the more discrepancy
between the reconstructed and true attenuation coefficients.

Figure 2.3: Cupping artifact. Beam hardening results in a cupping artifact at the
center of the circle (a) not corrected, (b) corrected. The x-ray beam becomes harder
through center and the center is erroneously assigned a lower gray value (CT
number).
(adapted from www.radiologycafe.com/radiology-trainees/frcr-physics-notes/ct-artifacts)
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In this work, volumetric images were corrected for beam hardening artefact. Iohexol has a
relatively high CT number compared to the agar tissue-equivalent phantom; thus, the
reconstruction process will have the effect of "cupping" artifact due to beam hardening. This
cupping artifact will result in inaccuracies in the measurement of the concentration that
remains in the carrier at each time point. In order to obtain accurate values of drug surrogate
contrast-agent concentration and diffusion distance, we must use an algorithm to correct our
data for beam hardening. In this project, we verified and used an algorithm that was
previously developed in-house [26].

2.2 Materials and Methods
2.2.1 Contrast Agent
A commercially available contrast agent; iodine-based Iohexol (Omnipaque™ 300, GE
Healthcare Canada Inc) was used in this study as a drug surrogate. Omnipaque 300 contains
300 mg of iodine per milliliter. It has an osmolality of 465 mOsm/L, absolute viscosity of
6.3 Pa.s, and specific gravity of 1.349 at 37°C. Iohexol is a common radiographic agent with
a molecular weight of 821 Dalton. The Wilke- Cheng equation proposes that there is a strong
correlation between the diffusion coefficient and molecular weight [27]; therefore, in this
work, we hypothesized that by understanding the relative diffusion characteristics of Iohexol,
we can infer the diffusion of commonly used antibiotics like Vancomycin into tissue in local
PJI treatment. A contrast-agent concentration was chosen so that we maintained sufficient
contrast in 3D reconstructed images throughout the duration of longitudinal micro-CT
scanning to track diffusion, but which did not cause unmanageable beam-hardening artifacts.

2.2.2 Experimental Design
Diluted iodinated contrast agent (containing 30 mg/mL of Iodine) was used as a surrogate to
mimic diffusion of drug in a two-part cylindrical agar sink, tissue-equivalent intact phantom.
Inner cylinder cores for each experiment were placed at the center of the outer cylinder.
Inner cores were surrounded by pure agar which formed outer annulus (Fig 2.4). We would
expect Iohexol molecules to move in a random way and diffuse from the area of the higher
concentration (cylindrical finite-source cores) to lower concentration (agar in outer annulus).
Three different cylindrical inner cores were fabricated: inner cylinders were made by adding
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the diluted contrast agent to agar and 2 different calcium sulfate matrices (i.e., Stimulan® and
Plaster-of-Paris). Agar and calcium sulphate matrices were evaluated as carriers for the drug
surrogate contrast agent, forming a model delivery system. Control phantoms were also
fabricated with the same dimensions but with no contrast agent added to the carrier matrices
at each experiment. Micro-CT imaging was used to measure the signal intensity at regular
time intervals.

Beam hardening correction was performed on projections to correct

associated artifacts (e.g., cupping) prior to reconstruction of 3D volumes for each time point.
3D volumetric data sets were generated from the corrected projections using a Feldkamp,
filtered, back-projection algorithm (eXplore speCZT, General Electric Healthcare, London,
Ontario) implemented in the scanner software [28]. In order to reduce noise and increase the
in-plane signal-to-noise ratio, the data were spatially-averaged along the z-axis. This axial
spatial-averaging along Z-axis was performed to improve the estimation of the radial
diffusion.

Figure 2.4: Two-part intact phantom – A schematic diagram of the diffusion
phantom, showing the finite-source (30 mg/ml Iohexol) “core” carrier material (agar or
CaSO4 matrices) in red and the tissue-equivalent “sink”(agar) in gray into which the
drug-surrogate contrast agent diffuses during the longitudinal micro-CT imaging
experiments.

32

2.2.3 Phantom Molds
To ensure consistency of a series of phantoms and facilitate repeated experiments, we
fabricated two custom molds. The first was an elastomer mold used for pouring an inner
core (17 mm diameter × 40 mm length) containing the drug-surrogate mixture in a carrier
matrix.

A two-part, “negative” housing-mold (Fig. 2.5) was created in CAD software

(Solidwork, Dassault Systemes).

The CAD files were then imported to a 3D-printer

(DREMEL 3D40, Dremel Digilab, Illinois, USA) and fabricated from Dremel polylactic acid
(PLA) filaments to create a two-part, silicone elastomer mold (Fig 2.5). The two-halves of
the elastomer mold were assembled, and the core matrix mixture was poured into the mold to
create the inner core of the phantom (Fig 2.5).
A second, 3D-printed, container-mold allowed for the pouring of an outer, thick-walled,
cylindrical annulus of pure agar, which acts as a tissue-equivalent sink for the drug-surrogate.
A 15-hour print time with 50 µm layer thickness was chosen to achieve a smooth finish and
minimum deviation from the CAD design (Fig 2.5). This radiolucent, PLA, container-mold
housed the phantom, and a 3-to-4 mm gap just underneath the lid, filled with de-ionized
water, helped to avoid interaction between the agar and air. Lateral ridges oriented the
phantom rotationally on the shoulders of the micro-CT bed for fast and accurate repositioning during longitudinal scanning. This mold had an outer diameter (OD) of 70 mm, a
height (H) of 53 mm, and wall thickness (WT) of 1.5 mm (Fig 2.5). Dimensions of the
container were chosen such that it was circumscribed entirely within a single-acquisition
field-of-view (FOV) of the micro-CT scanner (eXplore speCZT, General Electric Healthcare,
London, Ontario). The housing-container lid was designed with air- and water-filled
calibration chambers (Fig 2.6) to rescale gray-scale values to CT numbers in Hounsfield units
(HU). This mold was then reproduced to test different within different materials.
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Figure 2.5: Molds and final assembled diffusion-phantom (a) a two-part, 3D-printed,
“negative” mold used for making the silicone-elastomer, inner-core mold; (b) two-part,
silicone-elastomer mold used for casting the inner-core ; (c) Iohexol-loaded, inner-core
carrier of Stimulan matrix containing the drug-surrogate; (d) 3D-printed, PLA container
mold for housing the phantom showing the lid with air- and water-calibration chambers,
sealing-screws, and o-rings; (e) final, assembled, diffusion phantom showing the innercore carrier surrounded by the agar tissue-equivalent sink into which the contrast-agent
drug-surrogate diffuses.

Figure 2.6: Phantom container-mold – CAD drawing of the 3D-printed, PLA,
container-mold showing the (a) air and (b) water linear-calibration chambers in the
phantom lid; (c) the central alignment ring in the base for accurate placement of the carrier
core; and (d) the lateral ridges for rotational orientation.
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2.2.4 Phantom Preparation
Inner cylindrical cores were prepared from agar (A9799, Sigma-Aldrich, Oakville, Ontario,
CA), high-purity calcium sulphate (Stimulan® Rapid Cure, Biocomposites, Keele, U.K.) and
Plaster-of-Paris (DAP, Scarborough, Ontario, Canada) powders.
To evaluate Iohexol diffusion from an agar-cylinder carrier core into an agar annulus (i.e.,
single-phase diffusion), we prepared a sufficient agar volume solution for fabricating both
the inner core and outer annulus. The outer annulus and inner core have volumes of 145 cm3
and 9 cm3, respectively. A standard formulation was used to prepare the agar [29]. 300 ml of
de-ionized water was mixed at room temperature with 10.5 g agar powder. The mixture was
manually stirred until homogeneous and heated at a temperature of 90-95ºC for five minutes,
after which impurities were skimmed from the surface. Heating and skimming were repeated
two more times, for two additional minutes each time. The agar mixture was observed during
heating to achieve homogeneous appearance and to avoid boiling. A warm water bath of
approximately 85-90°C was used to maintain agar in the liquid phase during phantom
fabrication. Trapped air bubbles were then removed manually from the end product. A
vacuum chamber can also be used to remove small air bubbles in the liquid. To fabricate the
Iohexol-loaded agar inner core, 0.91 ml of Iohexol (Omnipaque 300, GE Healthcare,
Oakville, ON) was added to 8.17 ml of agar and mixed to obtain a homogeneous compound.
This mixture was poured into a custom, non-expandable, inert, elastomeric silicone mold
(Fig 2.5b) and was left undisturbed for one hour to let the agar mixture set. The two-part
silicone mold was separated, and the Iohexol-loaded agar core was removed. Then, the core
was centered within the custom, 3D-printed, PLA container-mold (Fig 2.5d). Pure agar was
then added to the core-periphery to form an annulus. The final assembled phantom was kept
undisturbed for approximately 60 minutes (Fig 2.5e). The container-mold lid was designed
with integral air- and water-filled calibration chambers (Fig 2.5d) for the CT calibration
purposes.
Iohexol-loaded Stimulan® and Iohexol-loaded plaster cores were both fabricated using the
same custom, non-expandable, inert, silicone elastomer mold. The contrast agent was
prepared by diluting 1.0 ml of full-strength, non-ionic Iohexol with 9.0 ml of de-ionized
water. 18.54 g of Stimulan® powder was weighed and then mixed with 10 ml of diluted
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Iohexol (30 mg/ml) as per the manufacturer's instructions and hand-mixed for 45 to 60 s to
form a homogeneous paste. The same formulation was used to make the Iohexol-loaded
plaster core. Specimens were kept at room temperature for 60 minutes to allow them to cure.
Control phantoms with no Iohexol were made out of pure Stimulan® and pure plaster within
the inner cores. Once again, cores were cast into pure agar and kept undisturbed at room
temperature for approximately one hour to allow the agar to set prior to micro-CT scanning.
De-ionized water was added on top of the agar to prevent evaporation. The water chamber
embedded in the container-mold lid was filled with de-ionized water for CT calibration
purposes. Final assembled phantoms were maintained at room temperature through the entire
duration of micro-CT scans.

2.2.5 Image Acquisition
Diluted Iohexol, a non-ionic iodinated contrast agent Omnipaque™, was used as a drug
surrogate and our tracer source. Control phantoms containing agar, Stimulan® and plaster
were scanned individually to achieve a baseline and corresponding CT number in Hounsfield
units (HU). Image acquisition started as early as 75 minutes after phantom fabrication.
Scanning was performed using a micro-CT scanner (eXplore speCZT, General Electric
Healthcare, London, Ontario). All samples were scanned with an X-ray tube peak-voltage of
90 kVp, tube current of 40 mA with a large focal spot. 900 projections, each 16 ms in
duration per frame, were acquired at 0.4° increments over a 360° rotation of the gantry. The
relatively short scan duration of 5 minutes was selected to minimize the amount of diffusion
occurring during each scan. The set of 900 projections was reconstructed into a threedimensional (3D) data set at a nominal, isotropic voxel spacing of 50 µm. Each 3D data set
was further spatially-averaged over 2 × 2 × 2 voxels, resulting in a final 875 × 875 × 572
voxel matrix with 100µm isotropic spacing. Since we aimed to track the diffusion of small
molecule drug surrogate, we needed to minimize the movement of our sample during
scanning. This micro-CT scanner utilizes rotating source-detector geometry allowing the
sample to remain stationary during the scanning process. The manufacturer-supplied
reconstruction algorithm was used for 3D images after performing custom beam-hardening
correction on all projections.
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Scanning was performed at 1.25, 3.58, 5.08, 8.08, 18.08, 30.08, 47.58, and 76.08 hours after
fabrication for the Iohexol-loaded agar core surrounded by agar. Image acquisition in
Iohexol-loaded Stimulan® and Plaster-of-Paris cores within an agar annulus continued up to
25 days to ensure sufficient time intervals for the diffusion of Iohexol through the calcium
sulphate carrier into agar at the periphery. Scanning was similarly performed at 1.25, 4.25,
8.25, 11.25, 23.5 hours after fabrication, then every 24 hours for the next seven days and
finally every 2 days for a further 17 days. Time zero was defined as the time of casting the
inner core within the outer pure agar annulus in the custom 3D printed PLA container.

2.2.6 Beam Hardening Correction
Diametric line profiles along axial CT slices exhibited considerable cupping artifacts within
images, due to beam hardening. Cupping artifacts result in errors in signal intensity
measurements at each time point that could lead to misrepresenting of contrast agent drugsurrogate concentration across the inner core and outer annulus, thus requiring a correction
algorithm. A beam hardening correction (BHC) algorithm was performed at each time point
on the acquired projections on the scanner prior to reconstruction. Diametric line profiles
were plotted at the exact same position to eliminate any error due to the repositioning of
profiles. Plots were compared to evaluate the efficiency of the beam hardening correction
(Fig 2.7). The correction algorithm will be described in detail.
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Figure 2.7: Beam hardening correction. Iohexol-loaded Stimulan® core in agar
scanned on SpeCZT (90 kVp, 40 mA), 1.25 hrs after fabrication, with CT axial slice and
corresponding diametric line profiles in the same axial CT slice. (a) no beam hardening
correction (b) with beam hardening correction. Cupping artifact caused underestimation
of attenuation within the inner core Iohexol-loaded matrix. CT numbers represent
relative Iohexol concentration.
Beam hardening correction was performed using an algorithm that was developed in-house
[26]. In this method, aluminum (Al) was used as a single calibration material to reduce or
remove signal intensity errors significantly (i.e., cupping artifact). The Al calibration
phantom was designed and manufactured in our laboratory. This Al phantom is a single
object comprised of eight coaxial cylinders with diameters ranging from 4.5 mm to 60 mm;
two opposite sides were flattened in a 20° arc to provide larger locations for measurement
(Fig 2.8). Image acquisition of the Al phantom was performed in the micro-CT scanner by
using an acquisition protocol (90 kVp, 40 mA) that is consistent with the protocol we used
for our diffusion experiments. We collected the transmission ratio values versus different
known thicknesses of Al phantom to verify the BHC algorithm for application in our
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experiments. Acquired data were then analyzed by analysis software (MicroView 2.2,
General Electric Healthcare, London, ON).
Custom regions of interest (ROIs) were selected at each individual known thickness of the Al
phantom and the CT transmission ratio of selected ROIs was measured automatically (in
arbitrary units) in MicroView. We collected Al data based on the range of the transmission
ratio values that we obtained in our diffusion experiments (i.e., maximum CT transmission
ratio of inner cores observed at the first scan time in diffusion phantoms). CT transmission
ratio versus different known Al thicknesses were plotted.
The plot represented non-linearity of thickness to transmission ratio (Fig 2.9). Data were
fitted to a non-linear

inverted one-phase (inverse) decay numerical function in Prism

(GraphPad 8.1.2 Software, Inc., La Jolla, CA, USA) with high accuracy (R2˃0.99) and
described by the equation ( 𝑌 = (𝑌0 − 𝑃) × exp(−𝐾 ∗ 𝑥) + 𝑃) where Y0 is the Y value
when x is zero. P is the Y value at x at infinite, K is rate constant; x is the known thickness.
This function was then implemented in custom software to create a look-up table to linearize
the log CT transmission [26].

Figure 2.8: Al Calibration phantom for beam hardening correction in micro-CT
and corresponding transmission image. (a) Al phantom was fabricated in house in
different thickness by gluing disks of various diameters together in an alternating
fashion. (b) Projection image from the scanner, obtained at 90 kVp and 40 mA.
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Figure 2.9: Plot of aluminum calibrator phantom thickness vs. gray-scale
values. We selected relative thickness of Al phantom based on the range of our data
(maximum Iohexol transmission ratio) and fitted a one phase (inverse) decay to
acquired data points at the application range. The fitted function parameters were
then used to create a look-up table to re-linearize the data.

2.2.7 Image Analysis
For each time point, the beam-hardening corrected projections were reconstructed into
volumetric 3D data, using Feldkamp’s filtered, cone-beam reconstruction algorithm [28] that
is implemented in the scanner software. Custom volumes of interest (VOIs) were created in
the air chamber and water-filled pocket available within each individual phantom (Fig 2.10).
Relative signal intensity within the volumes of interest were measured in MicroView. Signal
intensity calibration in Hounsfield units was then performed by rescaling grayscale values to
arbitrarily assigned values for air and water, -1000 and 0 Hounsfield (HU), respectively.
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Figure 2.10: CT number calibrators. Custom regions of interest (ROIs). in (a) air
chamber and (b) water-filled pocket within the phantom's lid to measure
corresponding signal intensity of air and water for calibration purposes.

To increase the in-plane signal-to-noise (SNR) ratio, the volumetric data was spatially
averaged along the axial direction to a voxel spacing of 5 mm.
This approach was used to reduce noise and enhance the characterization of two-dimensional
(2D) radial diffusion, while maintaining in-plane resolution of 0.1 mm. (Fig 2.11). At each
time point, diametric-intensity line profiles through the phantom were generated in order to
visualize 2D radial diffusion over time. To reduce line profile noise, minimize the
appearance of non-uniformities (e.g., possible air bubbles), and enhance diffusion
visualization, it was necessary to collect and average multiple line profiles. Custom software
was written to generate diametric intensity line profiles, placed radially around the
cylindrical phantom, and centered about the carrier core. The center of the carrier core was
determined, at each time point, by computing its unweighted centroid, using a standard
binary threshold technique. The diametric intensity line profiles, 65 mm in length, were
sampled every 50 µm and placed radially around the carrier core at one-degree increments, in
order to collect 180 profiles. The corresponding positional signal intensities of each line
profile were then averaged in order to produce a single, low-noise line profile for diffusion
visualization.
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Figure 2.11: Spatial averaging of axial CT slices. Demonstrates SNR of an averaged
diametric line profile through the Iohexol-loaded Stimulan® core in agar (a) 0.1 mm
spatial voxel spacing (b) 0.1 mm in-plane and 5.0 mm axial spacing and radially
averaged. Increase in signal-to-noise (SNR) ratio is observed in averaged slices in z-axis.

For analysis of single-phase diffusion, an intensity threshold was applied to determine the
Iohexol radial-diffusion distance outward from the Iohexl-loaded agar core. Early time
diffusion distances were obtained by adjusting a constant threshold of 300 HU and measuring
the subsequent radial diffusion at each time point up to 18 hours in MicroView (MicroView
2.2, General Electric Healthcare, London, ON).
In two-phase diffusion phantoms (i.e., Iohexol-loaded calcium-sulphate cores in agar
annulus), we again obtained the loss of contrast agent from the inner carrier core at each time
point. The custom cylindrical 3D volumes of interest within the inner cores were selected to
represent the spatial and temporal distribution of contrast agent in MicroView. Mean CT
numbers within the VOIs then linearly correlate with contrast agent concentration; the
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cumulative release amount was calculated by the law of conservation of mass at each timepoint.

2.2.8 Calculation of Diffusion Coefficient
The diffusion coefficient of the contrast agent was calculated by measuring the radial
diffusion distance and cumulative release amount within single-phase and two-phase
diffusion phantoms, respectively. In this work, two equations were used to calculate the
diffusion coefficient of the contrast agent drug-surrogate within the single-phase (i.e.,
Iohexol-loaded agar core in agar) and two-phase phantoms (i.e., Iohexol-loaded Stimulan®
core, or Iohexol-loaded plaster core).
The 2D diffusion equation that was used in this work represents the overall movement of
particles in 2D. Although each individual molecule (particle) exhibits random Brownian
motion that may not agree with the diffusion equation, as a group with the same initial and
boundary conditions, they represent smooth well-behaved statistical features that can be
captured by diffusion equation. In this work, instead of looking at the movement of one
particle, we image many particles as a group (i.e., Iohexol molecules) at each time point.
Below is a brief explanation of the 2D diffusion distance evaluation that used in this work,
which was described by Crank in 1975 [3].
The two-dimensional diffusion equation in Cartesian coordinates can be described as:
∇2 𝑃 −

1 𝜕𝑃
𝜕 2 𝑃 𝜕 2 𝑃 1 𝜕𝑃
=0 →
+
−
=0
𝐷 𝜕𝑡
𝜕𝑥 2
𝜕𝑦 2 𝐷 𝜕𝑡

(1)

The function P(x,y,t) gives the probability of the mean particle being present in the small
vicinity of the point (x,y) at time t and named probability distribution function.(1)
In probably
theory, "A distribution holds its statistical information in the moments of the distribution."
The constant 'D' is the diffusion coefficient of the particle in a given material and assumed to
be independent of position.
The diffusion equation can be derived by the solution of the partial differential equation
(PDE) using a Fourier transform. A boundary condition is applied by the assumption that at
an infinite distance from where particles originally introduced, the distribution probability
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should have zero chance for all times. In other words, the function P and all of its derivatives
are zero at |𝑥| = |𝑦| = ∞ and we would have,

𝑃(𝑥. 𝑦. 𝑡) = 𝐴

−(𝑥 2 +𝑦 2
(
)
𝑒 4𝐷𝑡

(2)

4𝜋𝐷𝑡

where (x2+y2) in the exponent is exactly r2 in polar coordinates, which can represent the
(2) the source
isotropic diffusion process on the x-y plane (i.e., only the radial distance from
matters). The solution to the 2D isotropic diffusion as presented by Crank is:

𝑃(𝑟. 𝑡) = 𝐴

−𝑟 2
(
)
𝑒 4𝐷𝑡

4𝜋𝐷𝑡

(3)

At first time point the molecules average position is where we originally introduce the
molecules in-plane (x=y=0). By taking advantage of the radial symmetry, diffusion
(3) distance
was presented to be linearly correlated to diffusion coefficient. In general, according to
Crank solution, for n-dimensional isotropic diffusion, the mean square distance is:
R2 = 2 n D t

(4)

Where R is radial diffusion distance (m), t is the relative diffusion time (s), and
D is the diffusion coefficient (m 2 s -1).
(4)
Diffusion distances of the contrast agent drug-surrogate were obtained from our acquired CT
image data. We then plotted the mean squared radial diffusion distance as a function of time
and performed linear regression within Prism (GraphPad 8.1.2 Software Inc., La Jolla, CA).
By application of this equation, we can conclude that the slope of our linear regression is
equal to 4D in two-dimensional diffusion. This approach was used to calculate the diffusion
coefficient of Iohexol within agar surrounded by agar.
The diffusion coefficient of Iohexol within calcium-sulphate carrier matrices was also
calculated in this work. Diffusion of Iohexol from plaster and Stimulan® cores in agar were
obtained using a mathematical drug-delivery model for cylindrical matrix carriers. We
implemented a mathematical model that describes the radial diffusion of drug molecules
through the cylindrical "diffusion-controlled" drug-delivery system. A diffusion-controlled
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drug-delivery system is defined as a system that is predominantly controlled by diffusional
mass transport. This model has been proposed in the literature by solving Fick's second law
of diffusion [1-3]. With consideration of initial and boundary conditions within the drug
delivery system, different equations can be extracted and simplified to measure the
approximate diffusion coefficient. The initial condition used for the model was a
homogenous distribution of a drug within the carrier, forming a monolithic solution (i.e., the
initial drug concentration is less than the drug solubility). The boundary condition was also
assumed to be "stationary," meaning that the device (i.e., 2 different calcium-sulphate
carriers in our experiment) dimensions are constant during diffusion [1].
Based on the initial and boundary conditions, Fick's Second Law has been solved and
described by an infinite series of exponential functions [1]. In this work, we used a late-time
approximation for cylindrical geometry proposed in the literature, where the diffusion
coefficient can be calculated by the known cumulative amount of drug released as a function
of time [1].
𝑀(𝑡)
4
𝐷𝑡(2.405)2
= 1−
exp
(−
)
(2.405)2
𝑀(∞)
𝑅2

(5)

where M(t) and M(∞) denote the cumulative amount of drug released at time t and in infinite
time, respectively; D is the diffusion coefficient of the drug within the system, and R
(5)
represents the radius of the inner core cylinder. Sets of experimental data were then fitted to
this equation to calculate the diffusion coefficient.
Cylindrical volume of interest (VOIs) were placed at the inner core of each phantom at
various time points. The relative CT number was measured automatically in MicroView. We
then used the linear relation between the CT numbers and concentration to obtain relative
concentration remaining in the inner core as a function of time. To agree with the law of
conservation of mass, the amount released can then be calculated by subtracting the amount
remaining in the core from the initial concentration measured at the first scan time for each
phantom.
Prism (GraphPad 8.1.2 Software Inc., La Jolla, CA, USA) was used, and the image data were
fitted to the equation No.5 to calculate diffusion coefficient.
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2.3 Results
2.3.1 CT Measurements
The initial CT numbers (HU) and standard deviations (HU) were measured in each of the
volumes of interest (VOIs) within the phantoms in MicroView, (as shown in Table 2.1).
Measured CT numbers were then used to linearly correlate the subsequent contrast agent
concentration at each time point to the CT numbers within each diffusion phantom. Custom
VOIs were selected at the first scan time within the inner core of each diffusion and control
phantoms. CT numbers at the outer edge of agar, sink annulus were also measured that
represent pure agar. All agar values at the annulus at first scan time showed similar CT
number. This result verifies the consistency of agar composition within different phantoms.
Table 2.1: CT numbers measured within each phantom. Custom volumes of interest were
selected at the first the scan time (i.e., 1.25 hours after phantom fabrication) within each
diffusion phantom.
phantom

Core CT Number

SD

Annulus CT Number

SD

(HU)

(HU)

(HU)

(HU)

Iohexol-loaded Agar

1380

±24

-32

±15

Iohexol-loaded Stimulan®

2490

±48

-30

±18

Iohexol-loaded Plaster-of-Paris

2485

±50

-32

±20

Pure Stimulan®

1780

±32

-32

±16

Pure Plaster-of-Paris

1790

±28

-33

±20

2.3.2 Diffusion Visualization
CT image data at each time point provides direct visualization of small-molecule diffusion
within the intact phantoms, due to the fact that corrected image signal intensity is linearly
correlated with Iohexol concentration. Images from CT volumes at different time points
within each phantom are consistent with that expected for the diffusion of molecules from a
finite-source into a surrounding medium. Diffusion proceeds, as expected, from higher to
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lower values across a concentration gradient. In our experiments, the flux of diffusion was
observed from inner-core matrices that had a higher concentration of Iohexol contrast agent
drug-surrogate into the agar sink at the periphery. For Iohexol-loaded agar cylindrical cores
within agar, images of CT axial slices showed almost uniform concentration of Iohexol after
76.0 hrs. (Fig 2.12).

Figure 2.12: CT slices of Iohexol loaded agar cylindrical core in agar. Diffusion process
of Iohexol contrast agent drug surrogate was characterized by down-gradient propagation,
spreading and smoothing over time (a) 1.25 hrs, (b) 5.08 hrs, (c) 8.08 hrs, (d) 18.08 hrs, (e)
47.58 hrs,(f) 76.08 hrs after phantom fabrication. CT axial slices showed almost uniform
concentration of Iohexol after 76.0 hrs.
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The diffusion rate of the contrast agent was also observed in the two calcium sulphate-based
matrices, either a Stimulan® or plaster-of-paris core within an annular agar sink. These CT
images showed a much slower diffusion rate of Iohexol from both calcium sulphate-based
carriers, while both carriers exhibited similar diffusion characteristics (Fig 2.13) In these
cases, the cylindrical core was still visible at late time points, due to the inherent contrast
provided by the remaining calcium-sulphate carrier.

Figure 2.13: CT slices of Iohexol loaded Stimulan® cylindrical core in agar. Iohexol
contrast agent drug surrogate diffuses slowly from the core into pure agar. Contrast agent
diffuses from the core primarily over the first 120 hours and remains relatively stable between
435 and 600 hours. a) 1.25 hrs, (b) 8.25 hrs, (c) 24.0 hrs, (d) 70.25 hrs, (e) 121.50 hrs, (f)
607.25 hrs after phantom fabrication.
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2.3.3 Quantitative Analysis of Line Profiles
Diametric line profiles across CT axial slices represent the corresponding signal intensity
(and hence contrast concentration) within each pixel along the line at that axial location;
moreover, CT signal intensity variation is linearly correlated with contrast agent propagation
within the phantom [23, 24]. Thus, diametric line profiles can be used to characterize twodimensional (2D) radial diffusion of contrast agent drug-surrogate diffusion from inner-core
matrices into the peripheral agar tissue-equivalent sink.
CT diametric line profiles versus position in pixels were plotted for each time point in Prism
(GraphPad 8.1.2 Software Inc., La Jolla, CA). Data were plotted for each phantom at various
time points, with the curves superimposed to compare relative 2D radial diffusion of the
contrast-agent drug surrogate through each of the carrier matrices.
Slow diffusion of Iohexol contrast agent from the Stimulan® core carrier and plaster core
carrier was observed, compared to the Iohexol-loaded agar core (Fig 2.14). In this case,
contrast agent diffuses from the calcium-sulphate core primarily over the first 120 hours and
remains relatively stable between 435 and 600 hours. The sharp boundary between the
calcium sulphate cores and the agar periphery was visible at all-time points; this was due to
the fact that the signal intensity in the core cannot be reduced below the offset value of the
pure calcium sulphate carrier (e.g., 1780 HU). Similar time-dependent line profiles were
observed for the Iohexol-loaded plaster of Paris core; these data were visually
indistinguishable from the Stimulan® results. Both of the calcium sulphate based carriers
were scanned for up to 25 days, to ensure that we observed the entire process of diffusion. At
early time points, Iohexol molecules diffused initially from the boundary of Iohexol-loaded
cores, which are in contact with the surrounding sink agar. This can be observed in CT line
profiles through axial CT slices. In these cases, the cylindrical core value can not fall below
the absolute CT number of pure plaster of paris and Stimulan®.
The evolution of contrast-agent concentration over time for the Iohexol-loaded agar core
within agar is shown in Fig 2.15. In this case, we observe a reduction in signal intensity
within the core, with a concurrent radial spread into the agar annulus. We also observe rapid
blurring of the boundary between the core and annulus, with Gaussian-like line profiles after
3 – 5 hours. There is a significant reduction of Iohexol concentration in the core after 76
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hours, approaching a uniform contrast-agent concentration across the entire phantom,
consistent with rapid diffusion.

Figure 2.14: Two-dimensional (2D) diametric line profiles within an axial CT slice.
(a) Iohexol-loaded Stimulan® cylindrical core and (b) Iohexol-loaded Plaster cylindrical
core surrounded by pure agar sink phantom at different time points. Iohexol contrast
agent drug surrogate diffused from core into agar periphery. Diffusion from the core was
reduced to a negligible value within approximately 145 hrs after phantom fabrication.
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Figure 2.15: Two-dimensional (2D), diametric, line profiles through an axial CT slice in
Iohexol-loaded cylindrical agar core surrounded by a pure agar sink at various time
points. Iohexol contrast agent drug surrogate diffused from the agar core into the agar
periphery. The Iohexol concentration observed within the phantom was significantly reduced
76.0 hrs after phantom fabrication.

2.3.4

Calculation of Iohexol Concentration

Linear correlation was used to estimate contrast agent concentration at the inner cores over
different time intervals [23, 24]. Inner core signal intensity (CT numbers) were obtained in
the

control

phantoms;

pure

agar,

Stimulan®

and

plaster

that correspond to -30±18, 1780±32, 1790±28 Hounsfield unit, respectively. All control
phantoms contain zero concentration of Iohexol contrast agent. Inner core CT numbers were
also measured within Iohexol-loaded agar, Iohexol-loaded Stimulan® and Iohexol-loaded
plaster cores. Linear regression then was applied in order to correlate the measured CT
numbers to the subsequent concentration of contrast agent drug-surrogate.
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𝑚𝑙

Linear regression results for iodine can be expressed as an equation 𝑆(𝑖) = 47 𝑚𝑔 × 𝐶𝑖 − 32
where S is the signal intensity in (HU), and Ci is the iodine concentration in mg/ml.

2.3.5 Diffusion Coefficient Calculation
The quantitative CT signal intensity data can be used to derive the diffusion coefficient from
both single-phase and two-phase diffusion phantoms. The estimate of the diffusion
coefficient in a single-phase diffusion experiment (i.e., Iohexol-loaded agar, cylindrical core,
in agar) was derived from the analysis of 2D (i.e., radial) diffusion distance over time, as
described in Equation 4. In this case, the early-time diffusion distance (R) was derived from
the CT images shown in Fig. 2.12, using a constant gray scale threshold to determine the
radial extent at each time point. These data were then used to determine the diffusion
coefficient, based on linear regression (Fig. 2.16). The linear regression shows an excellent
fit (R2˃0.99), allowing accurate determination of the slope, which is equal to 4D in twodimensional diffusion, where D is the diffusion coefficient (m2 s-1). The derived diffusion
coefficient, in this case, was 2.26 × 10-10 m2 s-1, which compares well with literature values
of 2.5 ×10-10 m2 s-1 for Iohexol in water [30].

Figure 2.16: Linear regression plot of radial diffusion distance vs. time. The slope of
the line represents 4D in two-dimensional diffusion in Iohexol-loaded agar core in agar.
The derived diffusion coefficient was equal to 2.26 × 10-10 m2 s-1.
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The estimate of the diffusion coefficient in a two-phase diffusion experiment (i.e., Iohexolloaded calcium-sulphate matrices, in agar) was derived from the calculation of the
cumulative release amount of the contrast agent drug-surrogate at each time point by
measuring the inner core loss. The cumulative release amount was calculated based on the
known inner core CT number, the linear relation between CT number and contrast
concentration, and the law of mass conservation. We then fit the cumulative release data to
the mathematical model for quantification of drug release from monolithic solutions (Eq.5);
the diffusion coefficient was then derived from the non-linear fit to this equation (Fig. 2.17),
with an R2˃0.99. Using this approach, we derived diffusion coefficients of 0.46 × 10-10 m2 s-1
and 0.85 × 10-10 m2 s-1 for Iohexol incorporated in Stimulan® and plaster cores, respectively.

Figure 2.17: Plot of the cumulative release of Iohexol contrast agent vs. time, (a)
Iohexol-loaded Stimulan® in agar (b) Iohexol-loaded Plaster in agar. diffusion
coefficients of 0.46 × 10-10 m2 s-1 and 0.85 × 10-10 m2 s-1 were calculated for Iohexol
incorporated in the Stimulan® and plaster cores, respectively.
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2.4 Conclusion
2.4.1 Image-based Diffusion Characterization
We have successfully developed a non-invasive, non-destructive, quantitative, micro-CT
technique to characterize real-time diffusion of small-molecules within an intact phantom.
We have shown that previously described mathematical approximations of diffusion
phenomena can be used to describe release kinetics from predominantly mass-diffusion
controlled delivery systems [1, 31]. We were able to fit our image-based diffusion data set to
mathematical models of diffusion and thereby calculate the diffusion coefficient. Our microCT technique has improved in-plane signal-to-noise ratio, allowing us to more accurately
estimate two-dimensional diffusion of a small-molecule contrast agent, acting as a drug
surrogate. The short scan time (i.e., five minutes) enabled us to minimize the amount of
diffusion that was occurring during each scan, while reducing exposure to a high X-ray dose.
X-ray dose should be considered in future applications of this method in animal models and
clinical testing.

Iohexol is one of the most common CT contrast agents, and it was

demonstrated in this work that it provides sufficient signal-to-noise ratio to characterize
relative diffusion during longitudinal scanning. Radial diffusion distance was obtained by the
application of a standard binary threshold technique at each time point for agar core. Since
CT numbers are correlated with the contrast agent concentration, it was also possible to
determine the mass loss of the contrast agent drug surrogate from the carrier core over time.
This provides a quantitative estimate of the cumulative release of contrast agent at each time
point. To the best of our knowledge, this is the first time that a CT-based, non-invasive
technique has been used to quantify small-molecule diffusion, with specific applications in
improving local drug delivery for ODRI.
The diffusion coefficients of Iohexol were calculated to be 2.26 × 10-10 m2 s-1 in agar, 0.46 ×
10-10 m2 s-1 in Stimulan®, and 0.85 × 10-10 m2 s-1 in plaster cylindrical carriers. As expected.
Iohexol molecules exhibited a higher diffusion rate in the water-based, carrier (i.e., agar)
compared to the calcium-sulphate based carriers (i.e., Stimulan® and plaster). Both calciumsulphate carriers exhibited similar relative diffusion characteristics over time, allowing us to
substitute plaster for Stimulan® in future experiments (and thereby reducing the cost of
research investigations in calcium-sulphate matrices). The diffusion coefficients for the two
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forms of calcium sulphate were found to be slightly different in this study. This may be
explained by the fact that Stimulan® is a highly-purified, medical-grade synthetic
recrystallized calcium sulphate alpha-hemihydrate, while conventional plaster is the betahemihydrate form of calcium-sulphate [32].

2.4.2 Limitations
There are certain limitations of this study; in this work, we used Iohexol, and we assumed
that Vancomycin follows relatively similar diffusion characteristics compared to Iohexol. As
we have described, the concept of tracking a surrogate molecule is not new; fluorescein (MW
332 Da) has been used as an optical tracer to study elution in calcium-sulphate carriers and
PMMA in ODRI, for example [12]. Our approach instead used an x-ray contrast agent
(Iohexol), with a molecular weight of 821 Da, which is much closer to that of commonly
used antibiotics in ODRI treatment, such as Vancomycin (MW 1449 Da).
Our in-vitro micro-CT test was performed under static conditions that did not include fluid
flow, load, or other stresses to which carriers are exposed in vivo. These factors would likely
affect the release of drug-surrogate molecules from each of the various materials. We
observed 2D diffusion characteristics. However, 3D evaluation would improve our
understanding of small-molecules diffusion within asymmetrical delivery carriers.
During the release of antibiotics from PMMA-based carriers, drug diffusion is the
predominant process, however, calcium-sulphate carriers are also biodegradable. Therefore,
resorption within these carriers is expected to increase the apparent rate of diffusion and this
process requires further consideration. Saturation of the surrounding tissue sink may also
affect the diffusion rate of drugs in local treatment. There are also different types of clinically
approved calcium-sulphate carriers, and this study only tested one (i.e. Stimulan®).

2.4.3 Applications
This study provided a controlled environment for the diffusion of a drug surrogate from a
finite source into a finite tissue-equivalent sink, which simulates the in-vivo conditions of
antibiotic delivery in ODRI treatment. However, the diffusion study was carried out in vitro
using intact phantoms. In the future, this approach can be applied to non-invasive
characterization of diffusion in-vivo, including animal models and clinical studies. Our
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technique can be very helpful, since it eliminates the need for invasive sampling of tissue and
enables us to non-invasively track and understand different mechanisms that ultimately may
affect drug release kinetics in animal models or clinical testing (e.g., resorption, carrier
swelling). By developing this micro-CT technique, we were able to obtain appropriate signal
intensity and concentration information to facilitate diffusion characterization of a contrastagent drug surrogate within various calcium-sulphate and agar carriers. This work could be
furthered by testing other types of carriers, such as PMMA bone cement (which is already
used clinically as an antibiotic carrier in two-stage revision surgery for infected orthopedic
implants) and calcium-phosphate carriers.
This micro-CT method also positions us to characterize the elution kinetics of small
molecules from enhanced carriers within a porous metal scaffold [25-28]. A highly-porous
metal scaffold may lead to a breakthrough in local antibiotic therapy for ODRI, as the
scaffold can separate the competing needs for mechanical strength, by providing structural
support while maintaining appropriate drug elution characteristics. Unfortunately, the
presence of a metal scaffold introduces the need for imaging artifact correction in micro-CT.
Thus, our future work (Chapter 3) will validate micro-CT diffusion measurements with a
drug-surrogate loaded carrier within the metal scaffold. We will also evaluate sequential
diffusion measurements near intact metal scaffolds in two dimensions. Further investigation
of the efficacy of a highly porous, metal scaffold containing antibiotic-eluting calciumsulphate is also needed, with the overarching goal to develop more effective revision
implants for ODRI management.
Our methods for elution tracking are flexible and can be applied to any contrast agent to
mimic various antibiotics, or for studies employing entirely different imaging modalities. It
may also be possible to extend the principles of non-invasive image-based methods for
studying diffusion to include the use of gadolinium-based MRI contrast agents, such as
Magnevist® (Bayer, Leverkusen, Germany) which has a molecular weight of 938 Da. The
artifact reduction (i.e. smaller signal void and lower field inhomogeneity) resulting from the
high porosity of the metal scaffold may potentially allow for quantitative susceptibility
mapping to reproduce the results of this study. Although MR-based contrast agent tracking is
unlikely to surpass the accuracy of micro-CT, MRI is likely to be commonly used for
monitoring patients in the clinic, due to excellent soft-tissue contrast and the lack of ionizing
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radiation. Further investigations into the use of clinical CT are also required, in order to
establish clinical relevance.

2.4.4 Summary
In this work, we have presented a quantitative micro-CT technique that can be used to
monitor the diffusion of small-molecules in an intact phantom. This technique has the
advantage that diffusion data can be obtained directly during longitudinal scans without the
need for invasive sampling of the tissue-equivalent sink, unlike previous studies that are
based on invasive sampling techniques [33-36]. CT measurements can facilitate quantitative
prediction of radial diffusion distance over time and cumulative amount of drug-surrogate
released from a finite-source into a controlled environment. These diffusion data can be
obtained by observing the subsequent CT value at each time point within volumes of interest.
We have shown that simple, mathematical approximations can be used to quantitatively
describe the drug release from a predominantly mass-diffusion controlled delivery system in
the absence of other factors that may affect diffusion (e.g., drug carrier resorption). Further
studies of diffusion of small molecules will help us to better understand the elution kinetics
of various drugs that are being used in local treatment. This will help us reach the long-term
goal of the development of more effective drug-delivery systems for local therapy.
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Chapter3
3

Mechanical Properties and Diffusion Characterization of
Highly Porous 3D-printed Scaffolds

3.1 Introduction
As describe in Chapter 1, there are unmet needs in the area of orthopedic-device-relatedinfection (ODRI), which includes infections near fracture fixation components in trauma
surgery [1-4], as well as peri-prosthetic joint infection (PJI) near orthopedic components
(e.g., hip, knee and shoulder joint replacements) [5-8]. Infection is a growing problem in
orthopedic surgery and is now the number one reason for early revision of hip and knee
replacements [9]. Local antibiotic delivery is commonly used as a gold-standard treatment to
eliminate infection in ODRI; however, it is often associated with poor clinical outcomes [10].
Poly (methyl methacrylate) bone-cement spacers are currently the most common carriers for
local antibiotic delivery in PJI. PMMA provides a level of mechanical strength for temporary
application in weight-bearing joints (i.e., ultimate strength of 70 MPa), however, with limited
capacity to be loaded with high-dose antimicrobial agents. It also exhibits relatively poor
antibiotic elution kinetics [11]. Hence, several alternative approaches have been proposed to
enhance local antibiotic delivery in PJI. Application of calcium sulphate-based and calcium
phosphate-based materials as antibiotics carriers can be considered as a practical approach to
overcome the poor elution kinetics of PMMA. These carriers exhibit enhanced elution
characteristics [12, 13], however, they exhibit poor mechanical properties in comparison to
PMMA. They are weak and brittle with low compressive strength; this is a barrier for these
carriers to be considered as a replacement for current PMMA carriers, and, as a result, their
application in PJI management has remained limited [14].
We propose an alternative approach for PJI management, using carriers that maintain
sufficient mechanical properties while incorporating a higher dose of the antimicrobial agent
within their structure and also exhibit improved elution characteristics. We proposed that
highly porous 3D-printed metal structures can be utilized for PJI management; these
structures can provide sufficient mechanical properties for load-bearing applications while
being capable of delivering antimicrobial agent to the target tissue due to their associated
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open pores. In this chapter, we investigate the development of hybrid structures,
incorporating a highly porous metal scaffold that can support virtually any carrier material,
with high-dose antimicrobial agents loaded into the carrier. This approach separates the
competing needs for mechanical strength and appropriate drug elution characteristics and
may lead to a breakthrough in local antibiotic therapy for PJI.
Biological materials are often porous; they exhibit optimized multi-functional structuring,
size-effect strengthening and high interconnectivity [15]. Recent advances in additive
manufacturing (i.e., laser powder-bed fusion) have enabled fabrication of porous metal
structures with such biological features and appropriate mechanical properties [16, 17].
Porous structures based on a gyroid lattice have been introduced to provide significant
advantages for orthopedic applications [18]. These porous structures can be manufactured by
laser powder-bed fusion in metal alloys. Gyroid-based scaffolds allow the adjustment of
mechanical properties, provide improved compressive fatigue resistance due to the lack of
stress concentrations, and may exhibit superior mass-transport properties [6, 18]. For these
reasons we believe that gyroid-based porous structures could be used to fabricate orthopedic
components with appropriate mechanical properties and high delivery capacity. This may
help in the development of a novel single-stage treatment strategy in PJI management. It may
be possible that such a scaffold could integrate into bone and be retained after an infection is
cleared, unlike current temporary spacers (i.e., PMMA), which must be replaced in a second
operation.
In this chapter, our first objective is to design a highly porous, 3D-printed gyroid-based
scaffold that can provide sufficient mechanical support and can be loaded with enhanced
antibiotics carriers (e.g., calcium sulphate).

Such scaffolds can be designed with

modifications to parameters to achieve porosity (i.e. void fraction) over the range of 60 to
90%. These values fall within the range that can be fabricated in metal using 3D-printing and
approximate the porosity of trabecular bone (50% - 90%) [19]. It will be essential to verify
that the porous scaffolds we design will maintain sufficient strength; thus, the mechanical
properties of our scaffold designs will be determined computationally by the application of
the finite-element method (FEM). Laser powder-bed fusion will then be used to fabricate
porous cylindrical gyroid-based scaffolds out of titanium alloy (Ti-6Al-4V). Our long term
goal is to test our porous metal designs with material testing equipment (according to

62

ISO5833 [11]) and verify an ultimate strength greater than 100 MPa, compared to PMMA
with an ultimate strength of 70 MPa. With these properties, we believe that the scaffold could
integrate into bone (due to resorption of carrier and subsequent osseointegration) and be
retained after an infection is cleared.
Our second objective is to characterize the diffusion of small molecules from calciumsulphate based carriers embedded within the porous metal scaffold. As described in chapter
2, we have developed a novel technique to measure small-molecule diffusion in an intact
phantom. Here, we will use our quantitative micro CT-based technique to evaluate diffusion
through a gyroid-based scaffold. Ultimately, this scaffold design, combined with the use of
enhanced medical-grade calcium-sulphate carriers (i.e., Stimulan®, Biocomposites, Keele,
U.K.), could provide a solution to current challenges in infection treatment in ODRI.

3.1.1 Gyroid-based Structures
Cellular/lattice structures can exhibit better material properties (e.g., structural strength) as
well as enhanced mass transport properties, compare to their bulk counterparts [20]. These
structures can be used in many biomedical applications. The mass transport property is an
essential feature for lattice structures when they are to be applied in applications such as the
development of drug delivery systems. Cellular/lattice structures have high interconnectivity;
this enhances their application as filling structures [17]. The pore networks of such structures
can be designed to reduce resistance to mass transport, shortening the diffusion path, and
increasing interconnectivity. Among cellular/lattice structures, the gyroid has promising
mass-transport properties; for example, Ma et al. report that the gyroid structure has better
interconnection and accessibility of fluids than a hexagonal structure [21] and has the
potential for application in bone-mimicking scaffolds.
The gyroid is a member of cellular/lattice structures that has been considered in different
biomedical applications such as orthopedic (i.e., bone-mimicking scaffolds) as well as tissueengineering applications [16, 17, 22]. Gyroid-based structures naturally exist in many
different systems in stable forms, such as butterfly wing scales [23], cell membranes [16, 24],
and block copolymers [25]. The gyroid is a member of triply periodic minimal surfaces
(TPMS) that divide space into two continuous phases [16]. The area fractions occupied by
the structure are approximately the same for various cross-sections, regardless of the cell size
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in gyroid-based lattices [26]. A TPM surface is a minimal surface that is repeated
continuously in three independent directions, which has constant mean curvature of zero at
all points. The symmetry of the elements can also be used to design various TPMS-based
geometries. In 1970, the gyroid was introduced by Alan Schoen, and he identified gyroid
surfaces as belonging to a family of triply periodic minimal surfaces that is free of selfintersections (i.e., their edges never cross each other) [27]. The gyroid has relatively good
mechanical properties compared to other TPMS cellular structures, and is one of the most
effective TPMS that can be utilized to create structures with robust mechanical performances
[15]. The gyroid structure also exhibits isotropic elasticity [17]. Moreover, such lattices
provide the advantage of a porous, open structure without significant stress concentrations
[18]. The gyroid is a highly adjustable structure with respect to mechanical strength and a
specific target architecture can be achieved by parametric design modification (e.g., changes
to unit cell size, wall thickness/pore size); this provides control over the porosity and hence
mechanical strength that is an advantage in orthopedic applications.
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Figure 3.1: Schematic of Gyroid-lattice structure, (a) shows one unit cell of a gyroid
structure where d is the pore size, T is the wall thickness and L is the length; (b) The unit
cell with the length of 6 mm that was used in this work; (c) three-dimensionally volume
rendering of a unit cell forming a cylindrical structure of 17 mm diameter × 40 mm
length.

Figure 3.2: Load-bearing surfaces of a gyroid-based cylinder at various cross
sections. Various cross-section shapes viewed from in plane shift of the two-dimensional
cross-section. The area fractions occupied by the structure are approximately the same
for all cross-sections.
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3.1.2 Selective Laser Melting
Traditional manufacturing methods such as casting, machining, and metal injection molding
have been used to fabricate porous metal scaffolds. However, these approaches provide
limited control over microarchitecture and surface features [28]. Although some metallic
lattice structures can be manufactured using traditional processes, using conventional
methods to fabricate complex structures like gyroid-based scaffolds is challenging [17]. In
this work, the fabrication of gyroid-based scaffolds was explored through an additive
manufacturing technique. Additive manufacturing is a collection of new manufacturing
techniques that allow layer-by-layer fabrication of three-dimensional (3D) structures. Recent
developments in additive manufacturing have made the fabrication of complex structures
possible. One example of a potential application that is in our interest is the ability to
fabricate porous metal gyroid-based structures that can be used in ODRI treatment.
Various cellular metal structures are manufactured by utilizing 3D printing (i.e., laser-power
bed fusion) [17]. Laser-power bed fusion is a promising laser-based additive manufacturing
technique in which an object is built layer-by-layer using a laser, heaters, and powdered
materials. By using laser-power bed fusion, we can fabricate scaffolds with complex
geometry, and we are able to convert a computer model into an actual structure directly with
high precision. In this technique, a focused laser beam is used to selectively melt thin layers
of metal powders together (e.g., Ti-6Al-4V); once the scanning of a layer is completed, a
new layer of powder is deposited, and fabrication of a new layer starts. This process is
repeated until the complete specimen is created [29]. Medical-grade Ti-6Al-4V is one of the
metals that can be successfully processed through laser-power bed fusion manufacturing. It is
notable that triply periodic minimal surface structures like the gyroid are also self-supporting,
which is another advantage for fabrication by laser powder-bed fusion (i.e., minimal supports
or no supports are required when 3D-printed ) [17].
In this work, we used a metal 3D printer (AM 400, Renishaw plc, UK) at the Additive
Design in Surgical Solutions (ADEISS) Centre at Western University to fabricate our gyroidbased structures. This machine has a laser power of 400 W with a laser spot size of 70 µm
and a layer thickness of 40 µm, and it is able to print parts using metal powder with 15-45µm
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grain diameter. This printer can be used to build complex medical-grade metal components
directly from three-dimensional design computer files (e.g., STL).

3.1.3 Finite element method
The finite element method (FEM) is a numerical method for analyzing complex engineered
structures. This numerical approach has been used for several years and can solve differential
equations, based on continuum mechanics models. This method can describe the
characteristics of engineered structures with complex initial and boundary conditions that are
impossible to examine using conventional numerical methods. In FEM, a complex structure
is broken down into a finite number of smaller pieces (elements), and the governing
equations are then formulated. These elements are then assembled to model the mechanical
behaviour of the structure [30]. Complex shapes or geometries (such as the gyroid) can be
discretized into a series of elements with known geometry and deformation behaviour within
a three-dimensional mesh. For example, in the case of static analysis, forces are applied to
the mesh model, creating deformation at the nodes of the elements that provide relative
values for displacement and stress distribution on the structure. Material properties must also
be assigned prior to the finite element solution. In this work, we performed a finite element
method on our gyroid-based structures to evaluate the displacement and stress distribution
under compression, for a range of porosities. We used a commercial FE software package
(ABAQUS, Dassault Systèmes, Vélizy-Villacoublay, France) for our loading simulations.

3.2 Material and Methods
3.2.1 Design of Porous Gyroid-based Cylinders
The design of the gyroid-based prototype was achieved using open-source software (Blender
2.78 3D software). The dimension of the unit cell was selected based on the previous
literature that has evaluated the mechanical properties of Gyroid structures for orthopedic
applications [18]. We also aimed to achieve optimum porosity, while preserving the
mechanical properties at an acceptable range for use in drug delivery.
A unit cell size of 6 mm × 6 mm × 6 mm in the three orthogonal directions (length × width ×
length) was selected. The gyroid-based structure was designed by 3D rendering of the unit
cell. Due to the symmetry of the surface, unit cells were patterned in three directions (x, y, z)
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to achieve a cuboid structure of 18 mm × 18 mm × 42 mm. The cuboid gyroid-based scaffold
was further transformed into a cylindrical structure using Boolean intersection with a
cylinder (17 mm diameter x 40 mm high).
In this work, we used wall thickness as a controlling parameter to vary the porosity of the
final scaffold. We created five gyroid-based cylinders with porosity consistent with that
observed in trabecular bone (i.e., 50% - 90% [19] ). We set the wall thickness of each
cylindrical gyroid-based structure to 0.85, 0.60, 0.40, 0.30, and 0.20 mm (denoted as G01,
G02, G03, G04, and G05, respectively). These cylindrical gyroid-based structures represent
approximate porosity of 60%, 70%, 80%, 85%, and 90%, respectively (Table 3.1).
The STL file that was exported from Blender did not provide sufficient triangle quality and
connectivity to be suitable for import, volume meshing, and loading in ABAQUS (Dassault
Systèmes, Vélizy-Villacoublay, France). These issues arise from the Boolean intersection
operation in Blender, which was used to create the cylindrical object from the rectangular
lattice of repeated gyroid unit cells. Additional improvements to the triangulated gyroidbased surface model were required in order to satisfy conditions necessary for ABAQUS to
produce a high-quality volume mesh. The desired mesh must exhibit sufficient resolution to
capture geometric features adequately and to also accurately resolve stress and strain
gradients during mechanical loading simulation. The STL file was imported into Geomagic
Studio (3D Systems, Rock Hill, SC, USA) for additional processing. Prior to surface mesh
improvement, a 0.2 mm thick section was removed from each end of the model by bisecting
with planes perpendicular to the long axis of the gyroid-based cylinder. The planar surfaces
resulting from this at the ends of the model were required for proper uniform distribution of
loading in simulation. Triangle improvement was carried out using a process of Laplacian
smoothing, triangle subdivision, and decimation with any geometric issues being corrected
via an automated verification tool contained in the software application between each step.
Once completed, and the geometry of the final model's validity confirmed, the final model
was exported once again in STL format for subsequent import into ABAQUS for tetrahedral
volume meshing and finite element analysis(FEA) setup.
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Figure 3.4: Top surface of gyroid-based cylinders of 17 mm diameter and 40 mm
length with various porosity. Renderings illustrate altering of the wall thickness and
porosity: G00) 0%, G01) 60%, G02) 70%, G03) 80%, G04) 85%, G05) 90%. All
gyroid-based cylinders were designed by periodically repeating a unit cell of 6 mm in
length in 3 principal spatial directions (x,y,z).

Figure 3.3: 3D rendering of Gyroid cylinder of 17 mm diameter and 40 mm
length. Unit gyroid cell of 6mm in length was repeated to create a cuboid structure,
and truncated to a cylinder using open-source design software (Blender 2.78 3D
software).
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Table 3.1: Gyroid-based cylindrical scaffolds (17 mm diameter and 40 mm length) with
varying porosity ranging from (60-90%)
Gyroid Cylinders

Unit cell Length

Porosity

Wall Thickness (mm)

(mm)

%

G01

6

60.02

0.85

G02

6

70.14

0.60

G03

6

79.83

0.40

G04

6

84.60

0.30

G05

6

89.70

0.20

3.2.2 Finite Element Analysis of Gyroid-based Cylinders
Mechanical performance of cylindrical Gyroid-based structures with porosity ranging from
60% - 90% were investigated under static compression load using a computationally finite
element method (FEM). The stress distribution, displacement, and effective uniaxial elastic
moduli were obtained by the commercially available finite element analysis software
(ABAQUS, Dassault Systèmes, Vélizy-Villacoublay, France). The results from FEM
analysis were used to select the optimum porosity for the fabrication of a porous scaffold in
titanium alloy (i.e., Ti-6Al-4V) and to perform a diffusion characterization experiment using
micro-CT.
Three-dimensional (3D) designs of the cylindrical gyroid-based scaffolds of various porosity
were imported into commercial finite-element analysis software (ABAQUS, Dassault
Systèmes, Vélizy-Villacoublay, France) for model assembly and loading simulation. Loading
and boundary conditions were consistent in all various designs of Gyroid cylinders. All the
samples were subjected to only a static compression load.
We applied a 10 kN compression load in the Z-direction as a ramp load with a step size of
0.001 per increment as the initial increment and the maximum increment of 0.5. ABAQUS
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software automatically controls the increments in between that are used during the solution.
In contact simulation, it is important to start with small initial increments to allow the
software to increase the increment based on the shared nodes at contact surfaces. A
distributed compression load was applied on the top surface of the gyroid-based cylinders
(Fig 3.5). A rigid plate with dimensions of 5 mm height (H) × 19 mm length (L) × 19 mm
width (W) was created to apply the distributed compression load on the top surface of the
cylinders. A full-contact interface between the plate and gyroid-based cylinder surface was
defined during the compression process. The material property of the plate was assigned to
be equivalent to elastic homogenous stainless steel (i.e., SS316L) with modulus of elasticity
of 193 GPa and a uniform Poisson’s ratio of =0.25. Each cylindrical structure was solved
for displacement in the direction of the applied static compression load. As described, the
increment solution available in the ABAQUS software was used to perform the compression
ramp load; cylinders were gradually loaded from 0% to 100%. The boundary condition for
the loading plate was displacement-rotation, and only one-degree of freedom was allowed in
the load direction.
Boundary conditions were applied on the cylinders for the finite-element analysis; the

Figure 3.5: Compression load and boundary condition of the gyroid-based
cylinder. A uniform distributed load of 10 kN was applied on a stainless-steel plate,
the boundary condition for the plate is displacement-rotation and only one-degree
freedom is allowed in the load direction. The cylinder is fully constrainted at the
bottom, while expansion of lateral surfaces is free to occur.
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cylinders were rigidly fixed (i.e., fully constrained) at the bottom to prevent rotation and
displacement in all degrees, but lateral expansion of all the samples was free to occur.
The material properties for the metal within the porous cylindrical scaffolds were set to
correspond to linear elastic homogeneous titanium alloy (i.e., Ti-6Al-4V) with modulus of
elasticity of 113.8 GPa and a uniform Poisson’s ratio of =0.342.
Linear, four-node tetrahedral elements were chosen for all simulations, which ensured high
material resolution within the elements of the FE models while maintaining reasonable
simulation times [31], typically on the order of 4 hours per simulation. Surfaces of Gyroid
cylinders were meshed with an element size of 0.25 mm. This allowed for an accurate
representation of the specific gyroid geometry and was found to be sufficient for representing
von Mises stress (i.e. maximum value changes are smaller than 1%). To ensure convergence
of this contact simulation, an increase in mesh density on contact surfaces was configured,
along with the use of small computation increments in the software.; elements on the contact
surfaces were allowed to be smaller (i.e., 0.15 mm) to guarantee the convergence. Elements
were connected to adjacent elements by nodes, thereby creating numerical representations of
the object geometry. The total number of elements was at a range of 1.4 - 1.6 million for this
simulation (depending on specific porosity). 8-node first-order linear hexahedral elements
were used for the plate, due to the simple geometry and to reduce the computational cost.

Figure 3.6: Finite element mesh of a gyroid-based cylinder. The cylinder was
discretized by linear, 4-node tetrahedral elements
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von Mises stress distribution under compression (and the resulting displacement in the load
direction) were obtained from the finite-element analysis for each cylindrical gyroid-based
structure. Previous literature has shown that the effective elastic modulus of a structure that
contains voids would be the ratio of the average stresses to the average strains that result in
the structure when it is subjected to pure compression on its outer boundary [32]. We have
approximated our porous cylindrical gyroid-based structures as homogenous elastic bodies
which contain periodically distributed voids of a common geometry (i.e., gyroid cell unit).
The effective (apparent) elastic modulus of each porous cylindrical structure was then
calculated by imposing the obtained displacement of each porosity under 10 kN compression
load into an equivalent homogeneous solid cylinder. Note that the apparent elastic modulus
calculated in this way is equivalent to compressive stiffness, for a homogeneous isotropic
material.
The porous gyroid-based cylinders were substituted with a solid cylinder of the same
dimension (i.e., 17 mm × 40 mm) in order to estimate the effective elastic moduli in
ABAQUS finite element software. The distributed ramp compression load of 10 KN was
applied on the top surface of the solid cylinder by a stainless-steel plate. The boundary
conditions were also consistent with the analysis of the porous gyroid-based structures. The
solid cylinder was fully restricted for displacement or rotation in any degree of freedom at
the bottom surface while the lateral surfaces were free to expand. The available obtained
displacement values for each porous gyroid-based cylinder were then applied to the
equivalent homogenous solid cylinder, and the subsequent effective elastic moduli for each
porosity were calculated.

3.2.3 Additive Manufacturing of Gyroid Cylinders
A metal 3D printer in the Additive Design in Surgical Solutions (ADEISS) Centre at Western
University was used to manufacture porous gyroid-based cylinders, using laser power-bed
fusion. A commercial 3D metal printer (AM400, Renishaw plc, UK) was used for the
fabrication process. This printer provides the capability of printing layers with a thickness of
40µm. Porous gyroid-based cylinders were fabricated out of powdered Ti6Al4V ELI-0406
alloy; this alloy comprises titanium mass fraction up to 90% with an average particle size of
15-45μm in diameter. Ti6Al4V was processed at the elevated melting temperature under
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400 W laser power with a beam size (i.e., laser spot size) of 70µm. This printer provides an
inert atmosphere, achieved by creating a vacuum before backfilling with high purity argon
gas through sealed and welded chambers to minimize the oxidation of the metal powder
during the printing process. Support filaments of 400 µm were used to anchor the printed
components to the build platform; these support filaments are crucial for the successful
completion of printing. When the entire part has been printed layer by layer as described in
the introduction, samples then undergo a standard heat treatment process for densification
and relief of any residual stresses. Heat treatment affects the mechanical properties of 3Dprinted objects; with post-heat-treatment on fabricated objects, fatigue life will be increased,
and objects will exhibit enhanced ductility [33]. Over the course of 60 minutes, the
temperature was raised to 350°C and held at this temperature for 30 minutes. The annealing
continued by increasing the temperature to 850°C, which takes 60 minutes. The 3D-printed
structures were then kept at 850 °C for 60 minutes. Objects were then left undisturbed to cool
down naturally. Heat treatment was performed while the cylinders were still were attached to
the build platform. After heat treatment, components were detached from the build plate by
manually cutting the support structure. Trapped loose powder was removed by ultrasonic
cleaning in a bath of pure ethyl alcohol, and cylinders were shot-blasted to minimize the
surface roughness. The mass of each fabricated gyroid-based cylinder was then obtained by
weighing the printed objects on a scale with 1 mg precision.
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G00

G01

G02

G03

G04

G05

Figure 3.7:Schematic of gyroid-based cylinders of 17 mm diameter and 40 mm
length with various porosity on the 3D-printer build-plate. G00) 0%, G01) 60%, G02)
70%, G03) 80%, G04) 85%, G05) 90%. The cylinders are attached to the build platform
through support structures ( blue filaments inside red circle) of 400 µm. Support filaments
are built using the same Ti6Al4v powder to avoid warping and distortion that may occur
due to the high processing temperatures.

3.2.4 Diffusion Characterization Within the Gyroid-based Cylinder
The overall goal of this work is to develop a 3D-printed porous gyroid-based titanium
scaffold that provides structural support while simultaneously incorporating carrier materials
to enhance small-molecule diffusion kinetics. Thus, we investigated small-molecule diffusion
in a 3D-printed metal gyroid-based cylinder with 80% porosity (i.e., G03). We utilized the
quantitative micro-computed tomography (micro-CT) technique that was described in
Chapter 2 to track the diffusion of a surrogate tracer molecule. This approach can help us to
better evaluate mechanisms of antibiotics elution, and to characterize the changes in elution
due to the presence of the metal scaffold. As in Chapter 2, we used a radiographic contrast
agent (i.e., Iohexol, molecular weight 821) as a drug-surrogate for one of the commonly used
antibiotics in PJI treatment. (i.e., Vancomycin, molecular weight 1449 Da).
Plaster-of-Paris (DAP, Scarborough, Ontario, Canada) was shown in Chapter 2 to exhibit
diffusion characteristics similar to commercially available medical-grade calcium-sulphate
carriers (Stimulan® Rapid Cure, Biocomposites, Keel, UK). For this reason, we used PlasterCaption:
of-Paris as a cost-effective substitute for Stimulan® to evaluate relative diffusion of small
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molecules through a calcium sulphate-based carrier matrix that had been introduced into the
gyroid-based porous scaffold.
We observed the diffusion of Iohexol drug-surrogate in a two-part cylindrical phantom
consisting of a gyroid-based cylinder that was loaded with Iohexol carrier and surrounded by
pure agar acting as a tissue-equivalent sink. This phantom was fabricated with the same
dimensions that were described in Chapter 2 to maintain consistency between all diffusion
experiments. To obtain Iohexol at a concentration of 30 mg/ml, we diluted 1.0 ml of fullstrength Iohexol (Omnipaque 300, GE, Healthcare, Oakville, ON) with 9.0 ml of de-ionized
water. 10 ml of Iohexol (30 mg/ml) was then mixed with 18.5 g of plaster powder. The
mixture was hand-mixed to achieve a homogenous paste. The paste was introduced into the
porous gyroid-based cylinder (17 mm diameter × 40 mm length) with a 10 ml syringe. A 3Dprinted PLA mold was used to position the cylinder in place during the injection of an
Iohexol-loaded plaster paste. Cylinder G03 with 80% porosity was selected to ensure
sufficient porosity for loading the drug-surrogate carrier, while retaining appropriate
mechanical properties. The loaded cylinder was then kept undisturbed at room temperature
for 60 minutes.
We used the same standard formulation that was described in Chapter 2 to prepare the agar
[34]. The gyroid-based porous cylinder (i.e., G03) was centered in the custom, 3D-printed,
PLA container-mold that was shown in chapter 2, Figure 2.5d. We poured pure agar into the
container to form an annular sink surrounding the porous cylinder. Air and water chambers
within the mold were used for CT calibration purposes, as described in Chapter 2.
A micro-CT scanner (eXplore speCZT, General Electric Health Care, London, Ontario) was
used for diffusion characterization. Image acquisitions were completed on the speCZT at an
X-ray tube voltage of 90 kVp and tube current of 40 mA, with a large focal spot in an 8.9 cm
bore. For each scan, 900 views were obtained at 0.4° increments over a 360° rotation of the
gantry at an exposure time of 16 ms per frame. These scan parameters resulted in an
acquisition duration (i.e., scan time) of approximately 5 minutes. Scans were acquired with
50 × 50× 50 µm voxel spacing. The scan acquisition parameters were kept consistent with
the diffusion experiments that were described in Chapter 2. Scanning was similarly
performed at 1.25, 4.25, 8.25, 11.25, 23.5 hours after fabrication, then every 24 hours for the
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next seven days and finally every 2 days for a further 17 days. Time zero was assumed to be
at the time of casting the Iohexol-loaded gyroid-based cylinder within the outer pure agar
annulus in the custom 3D printed PLA container.
We then applied a beam-hardening correction (BHC) algorithm to the acquired projections
prior to reconstruction [35]. The main cause of metal artifacts is the high attenuation of
metallic objects, which leads to X-ray beam-hardening of the polychromatic X-ray spectrum
and signal under-ranging [36].

For each time point, the corrected projections were

reconstructed into volumetric 3D data, using Feldkamp’s filtered cone-beam reconstruction
algorithm [37], which is implemented in the scanner software. Reconstructed threedimensional (3D) images were all averaged 2×2×2, result in final 100 × 100 × 100 µm
isotropic spatial resolution. Gray-scale values were rescaled to arbitrarily assigned values for
air and water, -1000 and 0 Hounsfield (HU), respectively. To increase the in-plane signal-tonoise (SNR) ratio, the volumetric data were spatially averaged in the Z-axis to a slice spacing
of 5mm to characterize the two-dimensional (2D) radial diffusion. The in-plane resolution
was maintained at 0.1 mm.
The loss of Iohexol contrast agent drug-surrogate from the porous Gyroid core was obtained
by measuring the corresponding CT number within the core at each time point. CT numbers
are assumed to linearly correlated with Iohexol concentration [38]. The diffusion coefficient
of the Iohexol drug-surrogate from the plaster carrier within the porous gyroid-based cylinder
was obtained by fitting the image data to the equation that was fully-described in Chapter 2
and shown below [39, 40]:
𝑀(𝑡)
4
𝐷𝑡(2.405)2
= 1−
exp
(−
)
(2.405)2
𝑀(∞)
𝑅2

(1)

The cumulative release amount of Iohexol tracer from the porous gyroid-based core into the
agar annulus was obtained at each time-point, based on the gray-scale values measured
within the core and the assumption of mass conservation. The image data was then fitted to
Equation 1 using non-linear Levenberg Marquardt fitting in Prism (GraphPad 8.1.2 Software,
Inc., La Jolla, CA).
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Figure 3.8: CT volume of gyroid-based cylinder with 80% porosity (G03) acquired
by isosurface volume rendering after beam hardening correction (BHC). The images
on the right show that the correction algorithm has resulted in significant reduction of
metal artifacts.

3.3 Results
3.3.1 Finite Element Results
Von Mises stress distribution and subsequent displacement in the load direction under a 10
KN compression force were obtained in ABAQUS software for all gyroid-based cylinders.
We assessed the effect of varying porosity on the von Mises stress distribution. Calculated
von Mises stress within the cylinder were compared to the yield strength of Ti6Al4V alloy
(equal to 970 MPa in compression [41]) to select a porosity that would be appropriate for the
CT-based diffusion experiment.
The maximum stress value in the FE result represented a single element in the mesh that was
seen to be on the edge of the contact surface between the gyroid-based cylinder and the load
plate for all porosity values. This artifactually high stress value was due to a limitation in
optimizing the mesh at the top surface of the gyroid, and also limitations in bisecting the top
surface with a plane perpendicular to the long axis of a cylinder, as described in the design
section (3.2.1). This value was significantly higher than the values within the cylinder
volume.
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Artifactually high-stress values were also observed at the outer surface of the gyroid-based
cylinders due to the application of a Boolean operation to intersect the cylinder and the cubic
volume design. This process resulted in connected bridges at the outer surface with no
support underneath, and these locations correspond to significantly high-stress values in FE
simulation (Fig 3.9).
As the artifactually elevated maximum von Mises values observed at the outer surfaces were
due to design, meshing and memory limitation, they were excluded from further analysis in
this work.

Figure 3.9: : Maximum Von Mises stress and regions with high-stress values at
outer surface. (a) the maximum stress value was observed at the edge of the top surface
due to the limitation in mesh sizing. (b) there were regions with no underlying support at
the outer surface that exhibited artifactually higher stress values due to design
limitations, these numbers do not represent the strength of structure and were eliminated
in this work.

79

Figure 3.10 depicts the von Mises stress distribution of cylinder G03, at different crosssections in the X-Z plane. As described in the introduction, this structure minimizes the stress
concentration, as can be seen across various cross-sections.

Figure 3.10: von Mises stress distributions of gyroid-based cylinder G03 (i.e., 80%
porosity). (a) artifactually higher values were observed at the outer surface due to small
regions with no support (b-d) these cross-sections better represent the smooth stress
distribution within the model at various cross sections obtained by shifting in the y
direction, perpendicular to the applied load.
The stress distribution was consistent across all modeled porosity values. However, higher
von Mises stress values were obtained as the porosity increases (Fig 3.11). Displacements of
the gyroid-based cylinders in the direction of compressive load were also recorded, as shown
in Table 3.2. The difference in displacement magnitude was expected; gyroid-based cylinders
exhibited greater displacement as the porosity increases. Effective elastic moduli of various
porosity values were calculated by using the equivalent solid cylinder under the same load
and boundary condition, as described in methods (3.2.2) and shown in Table 3.2
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Figure 3.11: The contours of von Mises stress at one fixed cross-section in the XZ plane for cylinder porosity (G01 – G05 ). The stress distribution is consistent
among all porosity values, however, higher von Mises stresses were observed as the
porosity increased.

Table 3.2: Calculated displacement and effective elastic moduli of gyroid-based
cylinders with varying porosity ranging from (60-90%). All samples were tested under 10
kN compression load in ABAQUS software. G00 is the solid cylinder of 17 mm ×40 mm out
of Ti6Al4V.

Caption:

Name

Porosity %

Displacement
(mm)

Effective Elastic
Moduli
(GPa)

G00

0

0.0152

113.8

G01

60

0.1050

16.5

G02

70

0.1500

11.5

G03

80

0.2050

8.4

G04

85

0.2200

7.9

G05

90

0.2500

7.0
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Analysis of displacement and calculated effective elastic moduli versus varying porosity was
performed using linear regression and non-linear Levenberg Marquardt fitting in Prism
(GraphPad 8.1.2 software, Inc, La Jolla, CA) respectively. A second-order polynomial
(quadratic) was the best-fit equation, with R2˃99 for the elastic moduli versus porosity plot.

(a)

(b)

Figure 3.12: Plot of FE analysis results of gyroid-based cylinders' vs varying porosity
(a) Linear regression of displacement vs porosity (R2 = 0.99) (b) Non-linear regression
(quadratic) effective elastic moduli vs porosity (R2 = 0.99)
We obtained the Von Mises stress values within the gyroid-based structures by manually
identifying elements that had higher values inside the volume. Maximum Von Mises stress
for G03 was reported at a range of 870-920 MPa, which is within the elastic region of
TI6Al4V, and just below the yield stress of 970 MPa. Cylinder G03 exhibited an elastic
modulus of 8.4 GPa, which is higher than PMMA (2-3 GPa) and exhibited 80% porosity;
thus G03 was selected to be loaded with the antibiotic-loaded carrier for the subsequent
diffusion experiment.
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3.3.2 Gyroid-based Cylinder Fabrication
Cylinders of various porosity values were fabricated using the 3D-metal printer
(AM400, Renishaw plc, UK). The gyroid-based cylinders were built over 7 hours and 30
minutes using the laser parameters described in the methods section (3.2.3).

G00

G01

G02

G03

G04

Figure 3.10: 3D-printed gyroid-based cylinders (17 mm length

G05

× 40 mm

diameter) with varying porosity values G00) 0% G01) 60 G02) 70% G03) 80%
G04) 85% G05) 90%. A 3D-metal printer (AM400, Renishaw plc, UK) was used
with laser power of 400W and laser spot size of 70 µm.
Fabricated cylinders were then weighed on a scale with 1 mg accuracy. G01, G02, G03, G04,
and G05 represented the mass of 13.777, 9.823, 6.283, 4.531, and 2.901 g, respectively,
compared to the solid printed cylinder (G00) of 39.103 g. This demonstrated that by
application
Caption: of porous lattice structures, we can obtain sufficient mechanical properties while
significantly reducing the weight of the component; thus, this approach can be used further to
develop lightweight orthopedic components.

3.3.3 Diffusion coefficient Calculation
The estimate of the diffusion coefficient of Iohexol drug-surrogate through a plaster carrier
within the gyroid-based porous structure of 80% porosity (i.e., G03) was derived from the
mathematical solution of Fick's second law for a cylindrical drug delivery system; this
solution was represented in the literature [39, 40] and described in Chapter 2 (section 2.2.8).
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Inner core gray-scale values at each time point were obtained and related to the Iohexol
concentration. The release amount was then calculated by subtracting the initial
concentration of Iohexol drug-surrogate from the remaining concentration level within the
core. We defined the equation based on release amount in Prism (GraphPad 8.1.2 software,
Inc, La Jolla, CA) for the application of non-linear regression and then fitted our CT-based
intensity data to Equation 1 (R2 = 0.98). The diffusion coefficient was then derived by nonlinear Levenberg Marquardt fitting.
The diffusion coefficient of Iohexol drug-surrogate through a calcium-sulphate based carrier
(i.e., Plaster-of-Paris) within a gyroid-based porous cylinder was determined to be 0.5 × 10-10
m2/s. This value is lower than that reported in Chapter 2 for a plaster core without the
presence of a metal scaffold (i.e., 0.85 × 10-10 m2/s).

Figure 3.11: Plot of the cumulative release of Iohexol contrast agent vs.
time. Contrast agent was embedded in plaster and was loaded into a gyroidbased cylinder of 80% porosity (i.e., G03) and surrounded with an annulus
of pure agar. The image data were fitted to the equation for a cylindrical
geometry drug delivery carrier; a diffusion coefficient of 0.50 × 10-10 m2/s
was calculated.
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3.4 Conclusion
3.4.1 Mechanical and Diffusion Characterization of a Porous Scaffold
We have developed a novel approach that can be used to address the current challenge of
local antibiotic treatment in orthopedic device-related infection (ODRI). We propose that
hybrid 3D-printed titanium scaffolds can provide structural support, while simultaneously
incorporating carrier materials with high-dose antimicrobial agents to enhance the elution
kinetics of conventional antibiotics in local drug delivery. Our target in this work was to
design a porous structure for ODRI treatment with an effective elastic modulus higher than
current bone-cement carriers ( i.e., PMMA with the elastic moduli of 2-3 GPa, [42]).
We have designed, fabricated, and tested a hybrid highly porous Ti alloy gyroid-based
scaffold capable of being loaded with a drug-surrogate incorporated within enhanced carriers
(i.e., calcium-sulphate). The results showed that the gyroid-based structure can be fabricated
out of Ti6Al4V using a laser power-bed fusion technique, and that by this approach, we can
improve the mechanical properties of the entire delivery system. The effective elastic moduli
of our designs were at the higher range (7-16.5 GPa), compared to the elastic moduli of
current PMMA (2-3 GPa). The mechanical properties of the gyroid-based lattice structure are
adjustable by altering the design parameters (i.e., wall thickness, unit cell size), and we can
modify our design according to the application. The ability to control the microarchitecture
of the gyroid structure (and thereby the mechanical properties) will enable the application of
these lattice structures for the design of orthopedic implants.
We were able to characterize small-molecule diffusion in an intact 3D phantom with the
presence of a metal structure, using our quantitative micro-computed tomography (microCT) technique and beam-hardening correction algorithm. This technique was based on
tracking a contrast agent surrogate tracer molecule (i.e., Iohexol) with a molecular weight
close to commonly used antibiotics. It has been shown that the open, accessible, gyroidbased architecture of the cylindrical scaffold that was fabricated by metal 3D-printing can be
loaded with drug-surrogate impregnated calcium sulphate carriers and contrast agent
molecules are observed to diffuse outward through the open-pore interconnected networks;
this indicates that gyroid-based lattices exhibit a smooth transition between unit cells for the
purpose of mass diffusion.
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The beam-hardening correction [35] that was developed in-house reduced the artifact due to
the presence of the metal structure, and it allowed us to determine the relative drop in grayscale value at each time point within the inner core. However, the signal intensity had a low
signal-to-noise ratio, making it difficult to analyze diametric line profiles over time. We
obtained the cumulative release amount of contrast-agent drug surrogate at each time point,
based on observed CT numbers, and thereby calculated the diffusion coefficient. We were
able to fit our CT-data to a mathematical diffusion equation and calculate the Iohexol
diffusion coefficient. Yao et al. previously described the application of a porous orthogonal
Ti scaffold loaded with antibiotic-impregnated PMMA in the treatment of bone infection,
and have also shown higher mechanical strength of the delivery system by the application of
a porous Ti 3D-printed structure while enabling more controlled diffusion mechanisms [43].
To the best of our knowledge, the current work is the first time that the diffusion
characteristic of a drug-surrogate has been investigated by a non-invasive technique (i.e.,
micro-CT) while the drug-surrogate is embedded in an enhanced carrier (i.e., calcium
sulphate) within a porous metal structure. The result demonstrated that the diffusion
coefficient of Iohexol through calcium sulphate would be reduced in the presence of a metal
structure, compared to pure calcium sulphate; this could provide an advantage by allowing
the antimicrobial agent to diffuse over a longer period of time and have an enhanced effect.

3.4.2 Limitations
The additive manufacturing process is associated with some limitations that should be noted
while fabricating porous structures. “Internal voids” or “void porosity” has been defined as a
porosity resulting from the fabrication process, and “porosity” refers to the open macroporosity of the porous structure (i.e., volume fraction) [18]. In this work, the gyroid-based
cylinders were considered to be completely solid in the FE simulations in ABAQUS, with no
“internal voids.” However, the manufacturing process would affect the result and may lead to
small internal voids associated with the structure; thus, we may have obtained higher
mechanical properties in finite element analysis, compared to future experimental mechanical
analysis by Instron material testing. It is worth noting that no obvious internal voids were
observed in the CT scan data (Fig. 3.8). Previous studies have shown that thicker walls
fabricated by metal 3D-printing would increase the likelihood of internal voids [18].
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The other implication of the possibility of internal voids resulting from additive
manufacturing is the nodal stress concentration at defects and voids. Although the gyroidbased lattice has minimum stress concentration naturally, artifactual defects due to additive
manufacturing may lead to a drop in fatigue resistance of the structure and may need to be
further addressed. If the gyroid-based scaffold undergoes mechanical failure in a loadbearing joint in the orthopedic application, it is potentially catastrophic and would cause
severe complications in vivo in the future; thus, understanding the worst-case mode is critical
before clinical application.
Here in this work, we used a 400 W laser power with a 70 µm laser spot size. However, the
optimization of the laser parameters for maximizing printed scaffold density and minimizing
defects can also be considered, and the selected laser parameters may not be the optimum to
achieve the highest density in the relatively thicker walls. The effect of refined laser
parameters can also be studied in the future.
Since metal implants in an orthopedic application are mainly loaded in compression, the
body of this chapter regarding the mechanical evaluation of the porous gyroid-based
cylinders is focused on compressive behavior. All samples were subjected to a 10 kN force,
and models were solved for the deformation in the direction of applied force. There have
been some previous studies on the tensile strength of gyroid-based lattice structures for
orthopedic applications; Kelly et al. performed an experimental analysis and represented
similar stretch-dominating behavior of titanium gyroid-based lattice structures, under both
macroscopic compressive and tensile loading. The results indicate that gyroid-based
structures are highly attractive for load-bearing applications and could be further studied for
our purpose in the application in drug delivery. Due to the dynamic loading of body joints invivo, fatigue strength analysis of gyroid-based structures could also be considered as a further
improvement in our finite element analysis to validate our proposed architecture. Kelly et al.
have also shown that gyroid-based lattice structures exhibit lower fatigue strength in tension,
compared to compression [18].
While the laser powder-bed fusion technique is quite mature, as mentioned, there is still the
risk that small structures will not be fully consolidated, which could compromise the
mechanical properties. It is important to verify that the porous scaffolds we produce have
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adequate strength in compression, consistent with the FEM predictions. We could further test
our 3D-printed structures using the material testing equipment in our lab (Instron 5966) that
will apply up to 10 kN compressive load. We can test our structures (using the ISO 13314
guidelines for porous materials) over the entire range of elastic and inelastic deformation to
determine the yield strength and ultimate strength. The ultimate strength of cortical bone is
about 140 MPa [44], so we will aim for at least 70% of that value with our scaffold; porosity
can be reduced, if necessary.

3.4.3 Implications and Future Applications
Recent advances have made it possible to use CT-image data of a patient's joint structure and
create a 3D-model by the application of CAD design, matching the patient anatomy to
fabricate custom patient-specific implants. Moreover, the gyroid-based unit cell can be
patterned to match any specific geometry and mechanical properties based on design
parameters; thus by taking the advantage of recent advances in computer aided design (CAD)
and additive manufacturing techniques, we can develop porous gyroid-based structures with
complex internal microarchitectures that have mechanical and transport properties tailored to
a specific orthopaedic application. This addresses the current challenges of two-stage
revision surgeries in peri-prosthetic joint infections. We have shown that gyroid-based
structures can carry antimicrobial agents for local treatment due to their porous nature, and
could be retained as the definitive fixture in revision surgery – potentially eliminating the
second stage of treatment.
Due to the porous nature of gyroid-based structures, we expect less image artifact caused by
the metal cylinder – not only in CT-images, but also in other imaging modalities (such as
MRI) compared to the bulk metal counterpart. This opens up a potential that may enable our
lab to include the use of gadolinium-based MRI contrast agents, such as Magnevist® (Bayer,
Leverkusen, Germany) in diffusion studies[45]. This MRI contrast agent has a higher
molecular weight of 938 Da (compared to Iohexol with a molecular weight of 821 Da) and
can be evaluated for quantitative diffusion characterization of small-molecule drugsurrogates within a porous structure in future studies to reproduce the result of this work.
The porous gyroid-based structure can also be studied in-vivo to evaluate the diffusion
characteristics of drug-surrogates in animal models. It is expected that the open

88

interconnected network of the gyroid-based structure would also facilitate wetting properties
in vivo. This may enhance the resorption of calcium-sulphate carriers, which would increase
the diffusion rate. The open interconnected network may also enhance osseointegration
following the resorption of a drug carrier; that possibility needs to be tested in the future.

3.4.4 Summary
This research demonstrates the capabilities of 3D metal printing to successfully fabricate
complex structures with desired mechanical properties, while not compromising the porosity
required to incorporate drugs in novel drug delivery systems. Recent advances in additive
manufacturing could open up several new developments in the design and fabrication of a
more advanced metal porous structure that could improve local drug delivery in PJI
management. Gyroid-based porous structures exhibit promising features for application in
local drug delivery, while the variation of design parameters enabled prescribed modulation
of porosity and interconnectivity, and thus resulted in varying effective mechanical
properties.
We were able to monitor the 2D diffusion of contrast agent drug surrogate through a hybrid
metal/calcium-sulphate scaffold to an agar tissue-equivalent sink. A combination of drug
impregnated carrier (i.e., plaster) within the porous structure resulted in a lower diffusion
coefficient, compared to its pure constituents. This may provide an advantage of elution over
a more extended period, which may have a stronger effect on Staphylococcus bacteria. We
can conclude that the application of a porous metal structure may be effective in the
treatment of peri-prosthetic joint infection by local drug delivery, and can be applied to other
applications in the future.
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Chapter 4
4

Conclusion and Future Directions

4.1 Summary
The ability to provide a better understanding of small-molecule diffusion characteristics is
essential to the development of improved, local, drug-delivery systems. Local drug delivery
is an important component in the standard treatment in orthopedic-device-related infection
(ODRI), but little is known of how the antimicrobial agents diffuse through the carriers into
the target tissue. In this work, we have characterized the two-dimensional (2D) diffusion of
small-molecules, non-invasively, using a micro-CT imaging technique. Conventional CT
imaging has been previously employed for studying the local diffusion characteristics of
platinum-based, clinically-administered drugs, such as carboplatin and cisplatin [1], which
are used in cancer treatment. Because they contain a heavy element, platinum, that
effectively attenuates X-rays, these drugs have intrinsically good image contrast and require
no additional contrast agent for image conspicuity. However, antimicrobial agents that are
used in infection treatment in ODRI are not easily detected in micro-CT imaging, as they do
not possess appropriate X-ray attenuating properties. Hence, a radiopaque contrast agent
(Iohexol) was chosen for use as a drug-surrogate in this study. Iohexol can act as a drug
mimic to visualize diffusion. Although it cannot be assumed that antimicrobial agents like
Vancomycin will exhibit exactly the same diffusion characteristics as the contrast agent, this
approach provided a better evaluation of the relative-diffusion characteristics of smallmolecules from a finite source to a surrounding environment in ODRI.
Iohexol has been well studied in biological systems [2] and has a molecular weight of 821 Da
that is close to commonly used antibiotics in ODRI treatment, such as Vancomycin with
molecular weight 1449 Da. A preliminary test was designed and performed by incorporating
the contrast agent into an agar carrier. The diffusion into the agar was tracked, which
validated our micro-CT, acquisition parameters, and artifact correction algorithms for
quantitative diffusion characterization. Further experiments were designed to determine the
diffusion characteristics of the drug-surrogate from enhanced carriers made of calciumsulphate based matrices (Plaster-of-Paris and Stimulan®).
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Both mineral-based and polymethylmethaclyrate (PMMA) carriers suffer from poor
mechanical strength, which is further degraded by incorporating a high-dose of antimicrobial
agents [3], therefore; in this work, we also proposed a new design for incorporating an
antibiotic carrier inside a porous metal structure. A carrier with good elution and resorption
properties can effectively deliver a sustained dose of antibiotic, while the metal structure
provides structural integrity.
Gyroid-based porous metal cylinders of various porosities were designed and 3D printed in a
Titanium alloy. Finite-element analysis was used to model our structures under compression
loads. The von Mises stress distribution and deformation of each porosity were modeled and
the effective elastic moduli were calculated. Gyroid cylinders were then fabricated using the
laser-power bed-fusion technique. We selected the gyroid cylinder of 80% porosity for
diffusion experiments because it represented the effective elastic moduli of 8.4 GPa that is
higher than PMMA (i.e., 2-3 Gpa), and its 80% porosity enabled the loading of a drugsurrogate, impregnated, calcium-sulfate carrier (plaster). The two-dimensional diffusion of
the Iohexol into an agar was then evaluated using the optimized micro-CT imaging
technique.
This micro-CT data enabled us to estimate the diffusion coefficient of the drug-surrogate
using mathematical models [4, 5]. The diffusion coefficient of Iohexol was calculated within
various carriers (Table 4.1). As expected, Iohexol molecules diffused at a higher rate in agar
carriers compared to polymeric, calcium-sulphate based matrices.
Signal-intensity profile plots across the diameter of the carriers were found to be a good
visual representation of the diffusion of Iohexol over time. Both calcium-sulphate matrices
exhibited similar signal-intensity profiles over time, thus validating the application of Plasterof-Paris as a viable, cost-effective alternative to Stimulan® for the study of diffusion. While
the two calcium-sulphate based carriers exhibited very similar relative diffusion properties, it
should be noted that in the calculation of quantitative, mass-transport properties, Plaster-ofParis yielded a higher value for the diffusion coefficient, compared to Stimulan®. This
difference in the quantitative material properties is primarily due to the two different forms of
calcium-sulphate that compose these two materials, as well as some possible additional trace
chemicals and impurities [6].
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For the case of Iohexol incorporated in the plaster carrier and then loaded into an 80%
porosity gyroid cylinder, the estimated diffusion coefficient dropped 41% compared to the
comparable pure plaster core with no metal gyroid. A similar reduction in diffusion rate by
the application of a porous, metal, 3D-printed, orthogonal structure was previously reported
[7], and is consistent with our results.
Metal structures exhibit high attenuation of X-ray photons that cause significant image
artefacts due to phenomena such as X-ray beam-hardening of the polychromatic spectrum
and scatter [8]. By implementing a post-processing, beam-hardening, correction algorithm
[9] developed in-house, and application of spatial averaging due to geometric symmetry, we
were able to reduce metal artifacts sufficiently to obtain the cumulative release amount of the
Iohexol [1] into the surrounding agar by measuring signal loss at the inner core.
Unfortunately, the signal-to-noise (SNR) ratio was not sufficient to track the radial-diffusion
distance longitudinally in the presence of a metal component.
Previous studies by Exner et al. have demonstrated the feasibility of conventional CT to
qualitatively monitor in vivo, local, drug pharmacokinetics from polymeric implants in smallanimal models [1, 10]. They tracked diffusion of drug-loaded (Iohexol and platinum-based
carboplatin), polymeric implants through the rat liver, before and after radiofrequency
ablation treatment. We have extended this approach by developing non-invasive, micro-CT
imaging techniques with sufficient spatial resolution to qualitatively and quantitatively track
drug pharmacokinetics through metal 3D printed implants for orthopedic applications.
To summarize, we believe that this study is the first to measure the diffusion coefficient of a
drug-surrogate within a porous, metal structure using a non-invasive, imaging technique to
acquire diffusion data and a fit to mathematical models. This in-vitro work offers a clear
understanding of the mechanism of mass-diffusion for local drug delivery because other
transport mechanisms, such as resorption, were not present in our phantom-based study [7].
Using the micro-CT imaging technique, image post-processing, porous-scaffold design and
manufacturing, and mathematical modeling techniques developed here for the in-vitro
experiments to measure passive diffusion, this technique could be further extended to animal
models to measure both passive diffusion and other possible mechanisms in-vivo that would
affect the diffusion rate of various drugs.
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Table 4.3: Iohexol diffusion coefficient (m2/s) through various cylindrical core carriers
to the annular, agar tissue-equivalent, sink. The diffusion coefficients were obtained by
fitting the CT-image data to the diffusion mathematical models.
Core Carrier
Agar

Diffusion Coefficient (m2/s)
2.26 × 10-10

Stimulan®

0.46 × 10-10

Plaster-of-Paris

0.85 × 10-10

Plaster-of-Paris in metal scaffold

0.50 × 10-10

4.2 Future Directions
Although in-vitro experiments are cost-effective approaches, in-vivo animal studies are the
next, critically important step in preclinical research to expand our knowledge and for the
development of new treatment approaches in ODRI. As is often the case, preliminary work
carried out in vitro is useful for refining techniques, choosing mathematical or theoretical
models, designing and building apparatus, and refining one’s basic understanding, all of
which is excellent preparation for extension to the in-vivo environment which is invariably
much richer and more complex. While we have shown in this work that it is possible to
measure small-molecule diffusion in intact phantoms using a drug-surrogate, this work does
not yield a full understanding of in-vivo diffusion due to other mechanisms that come into
play, such as the resorption of calcium-sulphate carriers, and wetting properties of the carrier
that affect the diffusion rate upon local treatment [11]. Other in-vivo transport mechanisms
can be explored and evaluated by implementing our micro-CT technique in animal models.
We first need to explore the in-vivo feasibility of this micro-CT imaging technique for further
studies.
Pre-clinical studies generally entail the use of small-animals, such as rats, and mice to be
more cost-effective [12]. Small-animal imaging applications require isotropic voxel sizes on
the order of 100 µm or less [13] – much smaller than is available on conventional CT
scanners. This work was performed on an eXplore SpeCZT micro-CT scanner (General
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Electric Healthcare, London, Ontario), which provides the fast scanning comparable to
clinical scanner with a high resolution – isotropic voxel spacing of 50 µm.
Since the animal has to be anesthetized during image acquisition to minimize subject motion,
the scan must be relatively short, so an imaging protocol with a 5-minute scan duration was
selected for our work. Small animals can also undergo multiple, short-duration scans at
defined time intervals to evaluate the diffusion for an extended period. One can try to make
intuitive guesses about how often scans are required in order to accurately characterize a
diffusion profile, but these preliminary experiments make it clear that our 5-minute scan
durations are short enough to sample the diffusion profile, while maintaining adequate image
quality.
In the extension of our in-vitro experiments using a drug surrogate to track the in-vivo
diffusion in animal-models, there are additional considerations such as toxicity. Fortunately,
the Iohexol employed in this study is a low-osmolarity, non-ionic, monomer, contrast agent,
and one of the most commonly used iodinated compounds that is routinely administered in
small-animal preclinical research studies, veterinary science [14], and clinical medicine.
Thus, we will be able to continue to use Iohexol in the study of diffusion in small-animal
models as a tracer source and also for further clinical tests.
Although our micro-CT image acquisition parameters can be directly implemented to
measure diffusion in small-animal models, it may achieve an insufficient signal-to-noise
(SNR) ratio to monitor in-plane diffusion, even after spatial averaging, due to the smaller
scale of animal subjects. This may lead to potential difficulties in obtaining the radial
diffusion distance of a drug-surrogate over time. However, based on previous literature [1,
10], we expected to achieve sufficient SNR to be able to quantitatively assess the tracer loss
from the core carrier over time, and thus calculate the cumulative release amount (based on
the law of conservation of mass).
Unfortunately, micro-CT scans come with an associated dose from ionizing radiation, that is
cumulative upon serial scanning protocols, and which may result in adverse effects on live
animals. Dose is a significant concern when the employed radiation interferes with the study
results – mainly in the evaluation of structural changes or tumor development. It is unknown
whether there would be any effect from this radiation on our diffusion measurements.
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However, Detombe et al. reported the effect of inducing dose on lung and myocardial tissue
of mice by performing scans twice weekly for 6 weeks with 80 kVp tube voltage and 50mA
tube current, resulting in a weekly dose of 0.84 Gy, and a total study dose of 5.04 Gy, and
reported no significant difference between the control group and the irradiated group [15].
Miyahara et al. performed a study on the effect of induced dose on mice by micro-CT using
90 KVp tube voltage (identical to ours) and showed that micro-CT, in general, induces a
very-low dose of radiation to a subject. For example, frequent micro-CT scans for a period of
4 weeks only give an average dose of 194.3 mGy, and he concluded that "It is unlikely that
an extremely-low dose can cause any acute radiation damage to mice"[16]. Still, the induced
radiation dose needs to be studied prior to the clinical implementation of this technique in
ODRI treatment.
To implement porous metal structures loaded with drug-surrogate impregnated carriers in
animal models, we also need to investigate the capability of the 3D metal printer to fabricate
gyroid-based, porous scaffolds at a small-animal scale. Due to the smaller size in the smallanimal models, the deviation of the CAD geometry design from an actual fabricated structure
needs to be addressed. However, our group has previously introduced the first metal hip
implant for hemi-arthroplasty in a rat using a metal 3D-printer [17]. This bodes well for the
capability of the in-house, metal 3D printer in the application of further diffusion studies in
small-animal models.
High concentrations of drug-surrogate contrast agent yield high signal intensity and facilitate
the ability to track diffusion, however, they also lead to image artifacts, such as beamhardening and increased scatter. A study to optimize the concentration level of Iohexol
contrast agent may be useful to balance the need for our beam-hardening, artifact correction
methods based with the desire for high signal intensity to track drug-surrogates over an
extended period of time.
Other imaging modalities such as magnetic resonance imaging (MRI) may prove useful in
the development of non-invasive diffusion characterization techniques. Using commonly
employed MRI contrast agents with higher molecular weights such as Gd-DTPA, tradename
Magnevist® (Bayer, Leverkusen, Germany), with a molecular weight of 938 Da, and a
comparison of the result with our CT-based experiments may shed further light on our
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understanding of diffusion in small-molecules. The use of a variety of contrast agents opens
up the possibility to investigate the effect of molecular weight on diffusion. Additionally, the
use of MRI negates any ionizing radiation dose burden that is inherent with micro-CT based
studies.
Diffusion coefficient values calculated in this work can also be used in computational models
to validate diffusion models based on our experimental evidence. Validated numerical
models facilitate further investigation, while minimizing the need for animal or human
subjects. They also provide a framework for work in more complex 3D structures and for the
evaluation of the effect of geometry on diffusion. Both CT-derived, patient-specific, or
generic anatomical geometry can also be incorporated into numerical diffusion models to
study diffusion in ODRI. These models allow us to manipulate a variety of transport
properties and investigate the extent to which they are important in the diffusion
mechanisms.
The level of osteo-integration into the porous, gyroid scaffold can also be studied via
histology in small-animal models. While calcium sulphate has superior elution kinetics
compared to PMMA carriers, it also exhibits an osteoconductive nature that can improve
bone formation. Calcium-sulphate based materials are currently applied to implant substrates
to improve bone-implant fixation [18], thus, we expect that resorbed calcium-sulphate carrier
can be replaced by bone formation within the open-pore network of our proposed gyroidbased scaffold. This would improve the mechanical properties of the structure and would
facilitate the permanent retention of the porous scaffold, and may even lead to the
elimination of two-stage revision surgeries.
PMMA is the current clinical standard material for carriers, but it is not ideal, and others with
different diffusion, resorption, and mechanical properties may demonstrate superior
performance. We started this research with the relatively low-risk material for current
PMMA carriers, and evaluated the diffusion of tracers through calcium-sulphate matrices.
We can also explore more innovative approaches in the future for antibiotic release, using
stimuli-responsive materials. The first group of materials to be investigated could include
pH-sensitive, acetal-containing polymers that can be used to encapsulate antimicrobial agents
[19]. This may be an effective strategy for controlled release, because pH is reduced in tissue
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near an infection [20]. The polymers can be designed to degrade at varying rates depending
on the acetal structure, thereby releasing drug-surrogate over controllable time frames and in
a pH-dependent manner [21]. Temperature change can also be used as a stimulus,
particularly in conjunction with RF-induced hyperthermia. We can employ biodegradable
poly(ester amide)s (PEAs) that undergo a glass transition just above 37C [22]. Upon
transition, the diffusion rate of the drug out of the polymer increases [23]. The polymers can
be synthesized and characterized by methods including NMR spectroscopy, thermal analysis,
and size-exclusion chromatography. Chemical modifications can also be introduced, as
needed, to enhance coating and adhesion to the porous, metal scaffolds, and micro-CT can be
performed to monitor diffusion through suggested novel carriers.
Heating titanium gyroid-based components within the body to a temperature (typically over
55°C) is useful to the disruption of harmful biofilms in case of permanent implantation of
porous scaffolds. In the future, we could take advantage of the phenomenon of highfrequency, electromagnetic field use for non-contact heating of metals [24] and we can
investigate the effects of heating gyroid-based porous-scaffold surfaces (rather than the
interior) by using coils operating at high frequencies to obtain the “skin” effect [25].
Accurate measurements of the implant and nearby-tissue temperatures should be performed
to avoid inadvertent damage to the adjacent tissue. It is expected that temperatures above
50°C may cause damage to healthy tissues (i.e., bone, muscle, vessels), and that sustained
temperatures above 70°C cause tissue necrosis [26-28]. Once we have developed the required
tools to heat titanium scaffolds and measure surface temperatures, we can investigate the
effect of hyperthermia on bacteria and biofilms in vitro and further in animal-models.
Despite the lack of in-vivo data in this work, certainly our ultimate goal is to develop
techniques that will reduce the number of costly (and time-consuming) two-stage therapy in
ODRI, specifically PJI. Towards this objective, we have provided a quantitative technique to
track diffusion characteristics of small-molecules through carriers embedded in a highlyporous metal scaffold. We are not the first group to suggest porous structures [29], but, to the
best of our knowledge, we are the first that have described the use of calcium-sulphate
matrices within a titanium gyroid-based porous structure for infection treatment. Application
of porous structures can also be used to provide local delivery of other agents such as growth
factors, bone morphogenic protein, and cancer drugs, in the future.
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